EP4281570A1 - Plate-forme de synthèse in-vitro pour la génération d'isoprénoïdes - Google Patents
Plate-forme de synthèse in-vitro pour la génération d'isoprénoïdesInfo
- Publication number
- EP4281570A1 EP4281570A1 EP22700507.1A EP22700507A EP4281570A1 EP 4281570 A1 EP4281570 A1 EP 4281570A1 EP 22700507 A EP22700507 A EP 22700507A EP 4281570 A1 EP4281570 A1 EP 4281570A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- kinase
- diphosphate
- process according
- seq
- hemiterpene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003505 terpenes Chemical class 0.000 title abstract description 56
- 238000000338 in vitro Methods 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 365
- 230000008569 process Effects 0.000 claims abstract description 360
- 239000001177 diphosphate Substances 0.000 claims abstract description 292
- 235000011180 diphosphates Nutrition 0.000 claims abstract description 292
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 186
- 239000010452 phosphate Substances 0.000 claims abstract description 186
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 185
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 185
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 180
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract description 136
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 92
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 150000004712 monophosphates Chemical class 0.000 claims abstract description 35
- 230000000865 phosphorylative effect Effects 0.000 claims abstract description 32
- -1 sesquiterpene diphosphate Chemical class 0.000 claims description 176
- 102000004190 Enzymes Human genes 0.000 claims description 165
- 108090000790 Enzymes Proteins 0.000 claims description 165
- 229930004725 sesquiterpene Natural products 0.000 claims description 116
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical group CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 claims description 81
- 108090000769 Isomerases Proteins 0.000 claims description 61
- 102000004195 Isomerases Human genes 0.000 claims description 61
- 230000015572 biosynthetic process Effects 0.000 claims description 58
- 238000003786 synthesis reaction Methods 0.000 claims description 58
- 238000002360 preparation method Methods 0.000 claims description 56
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical group CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 claims description 54
- 102000001253 Protein Kinase Human genes 0.000 claims description 50
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 45
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 45
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 39
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical group CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 claims description 36
- 230000026731 phosphorylation Effects 0.000 claims description 31
- 238000006366 phosphorylation reaction Methods 0.000 claims description 31
- 108060004127 isopentenyl phosphate kinase Proteins 0.000 claims description 25
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 claims description 23
- 108060006633 protein kinase Proteins 0.000 claims description 22
- 101710093888 Pentalenene synthase Proteins 0.000 claims description 16
- 101710115850 Sesquiterpene synthase Proteins 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 claims description 10
- 108010065958 Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 claims description 6
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 6
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 6
- 102100039618 Isopentenyl-diphosphate delta-isomerase 2 Human genes 0.000 claims description 5
- 241000205014 Methanolobus tindarius Species 0.000 claims description 5
- 108030001670 (2E,6E)-farnesyl diphosphate synthases Proteins 0.000 claims description 3
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 description 146
- 125000003275 alpha amino acid group Chemical group 0.000 description 63
- 229930003658 monoterpene Natural products 0.000 description 59
- 235000002577 monoterpenes Nutrition 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 54
- 229920000388 Polyphosphate Polymers 0.000 description 41
- 239000001205 polyphosphate Substances 0.000 description 41
- 235000011176 polyphosphates Nutrition 0.000 description 41
- 229930004069 diterpene Natural products 0.000 description 37
- 238000011069 regeneration method Methods 0.000 description 37
- 150000003535 tetraterpenes Chemical class 0.000 description 34
- 235000009657 tetraterpenes Nutrition 0.000 description 34
- 239000007788 liquid Substances 0.000 description 27
- 239000012429 reaction media Substances 0.000 description 26
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 24
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 24
- YVLPJIGOMTXXLP-UHFFFAOYSA-N phytoene group Chemical group CC(C)=CCCC(=CCCC(=CCCC(=CC=CC=C(CCC=C(CCC=C(CCC=C(C)C)C)C)C)C)C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 24
- 235000007586 terpenes Nutrition 0.000 description 24
- 150000002773 monoterpene derivatives Chemical class 0.000 description 21
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 20
- 235000019529 tetraterpenoid Nutrition 0.000 description 17
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Chemical compound C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 16
- NDVASEGYNIMXJL-UWVGGRQHSA-N (-)-sabinene Chemical compound C=C1CC[C@]2(C(C)C)[C@H]1C2 NDVASEGYNIMXJL-UWVGGRQHSA-N 0.000 description 16
- NDVASEGYNIMXJL-UHFFFAOYSA-N beta-sabinene Natural products C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 16
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 16
- 102100031065 Choline kinase alpha Human genes 0.000 description 14
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 14
- 230000008929 regeneration Effects 0.000 description 14
- XVULBTBTFGYVRC-HHUCQEJWSA-N sclareol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@](O)(C)C=C)[C@](C)(O)CC[C@H]21 XVULBTBTFGYVRC-HHUCQEJWSA-N 0.000 description 14
- 108010092060 Acetate kinase Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- ATCICVFRSJQYDV-UHFFFAOYSA-N (6E,8E,10E,12E,14E,16E,18E,20E,22E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,26,30-dodecaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C ATCICVFRSJQYDV-UHFFFAOYSA-N 0.000 description 12
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 12
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 108010018888 Choline kinase Proteins 0.000 description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- 102000024323 dimethylallyltranstransferase activity proteins Human genes 0.000 description 12
- 108040001168 dimethylallyltranstransferase activity proteins Proteins 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- 235000011765 phytoene Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 12
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 11
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 11
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 11
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 11
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 11
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 11
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 11
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 11
- 229940045189 glucose-6-phosphate Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 229960004999 lycopene Drugs 0.000 description 11
- 235000012661 lycopene Nutrition 0.000 description 11
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 11
- 239000001751 lycopene Substances 0.000 description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 11
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 10
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 10
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 10
- 238000009833 condensation Methods 0.000 description 10
- 230000005494 condensation Effects 0.000 description 10
- 108010071062 pinene cyclase I Proteins 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108030004087 (+)-sabinene synthases Proteins 0.000 description 8
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 8
- 108010055400 Aspartate kinase Proteins 0.000 description 8
- 108010089895 Branched-chain-fatty-acid kinase Proteins 0.000 description 8
- 108700024126 Butyrate kinases Proteins 0.000 description 8
- 108020004827 Carbamate kinase Proteins 0.000 description 8
- 108030007102 Formate kinases Proteins 0.000 description 8
- 108030002417 Glutamate 1-kinases Proteins 0.000 description 8
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 8
- 108090001084 Propionate kinases Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- STJIISDMSMJQQK-UHFFFAOYSA-N furan-3-ylmethanol Chemical compound OCC=1C=COC=1 STJIISDMSMJQQK-UHFFFAOYSA-N 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229930002839 ionone Natural products 0.000 description 8
- 150000002499 ionone derivatives Chemical class 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 8
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 8
- JEYLKNVLTAPJAF-UHFFFAOYSA-N xi-3-Methyl-3-buten-2-ol Chemical compound CC(O)C(C)=C JEYLKNVLTAPJAF-UHFFFAOYSA-N 0.000 description 8
- 108030004098 (-)-sabinene synthases Proteins 0.000 description 7
- XVULBTBTFGYVRC-UHFFFAOYSA-N Episclareol Natural products CC1(C)CCCC2(C)C(CCC(O)(C)C=C)C(C)(O)CCC21 XVULBTBTFGYVRC-UHFFFAOYSA-N 0.000 description 7
- 102000057621 Glycerol kinases Human genes 0.000 description 7
- 108700016170 Glycerol kinases Proteins 0.000 description 7
- LAEIZWJAQRGPDA-UHFFFAOYSA-N Manoyloxid Natural products CC1(C)CCCC2(C)C3CC=C(C)OC3(C)CCC21 LAEIZWJAQRGPDA-UHFFFAOYSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 125000003835 nucleoside group Chemical group 0.000 description 7
- 108020000161 polyphosphate kinase Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 6
- NEJDKFPXHQRVMV-HWKANZROSA-N 2-Methyl-2-buten-1-ol Chemical compound C\C=C(/C)CO NEJDKFPXHQRVMV-HWKANZROSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 102000002281 Adenylate kinase Human genes 0.000 description 6
- 108020000543 Adenylate kinase Proteins 0.000 description 6
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 6
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 6
- 102000005133 Glutamate 5-kinase Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 6
- 229930010555 Inosine Natural products 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- ATCICVFRSJQYDV-DDRHJXQASA-N Neurosporene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C ATCICVFRSJQYDV-DDRHJXQASA-N 0.000 description 6
- 108010044790 Nucleoside-Phosphate Kinase Proteins 0.000 description 6
- 102000005811 Nucleoside-phosphate kinase Human genes 0.000 description 6
- 102100024279 Phosphomevalonate kinase Human genes 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 108030004291 Sclareol synthases Proteins 0.000 description 6
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 description 6
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 description 6
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 6
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 description 6
- 229940104302 cytosine Drugs 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 229960003786 inosine Drugs 0.000 description 6
- 235000008665 neurosporene Nutrition 0.000 description 6
- 108091000116 phosphomevalonate kinase Proteins 0.000 description 6
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 6
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 description 6
- 235000002677 phytofluene Nutrition 0.000 description 6
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229940031439 squalene Drugs 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229940113082 thymine Drugs 0.000 description 6
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- 239000005973 Carvone Substances 0.000 description 5
- 108010015895 Glycerone kinase Proteins 0.000 description 5
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 5
- 229910004856 P—O—P Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000021466 carotenoid Nutrition 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 125000004437 phosphorous atom Chemical group 0.000 description 5
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 5
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108030004092 (+)-car-3-ene synthases Proteins 0.000 description 4
- WTOYNNBCKUYIKC-JMSVASOKSA-N (+)-nootkatone Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CC(=O)C=C21 WTOYNNBCKUYIKC-JMSVASOKSA-N 0.000 description 4
- QEBNYNLSCGVZOH-NFAWXSAZSA-N (+)-valencene Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CCC=C21 QEBNYNLSCGVZOH-NFAWXSAZSA-N 0.000 description 4
- 239000001890 (2R)-8,8,8a-trimethyl-2-prop-1-en-2-yl-1,2,3,4,6,7-hexahydronaphthalene Substances 0.000 description 4
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 4
- 108030004947 (R)-limonene synthases Proteins 0.000 description 4
- 108030004937 (S)-beta-bisabolene synthases Proteins 0.000 description 4
- 108010012839 (deoxy)nucleoside-phosphate kinase Proteins 0.000 description 4
- 108030001894 15-cis-phytoene synthases Proteins 0.000 description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 4
- ZCHHRLHTBGRGOT-UHFFFAOYSA-N 2-hexen-1-ol Chemical compound CCCC=CCO ZCHHRLHTBGRGOT-UHFFFAOYSA-N 0.000 description 4
- 101710188934 2-phosphoglycerate kinase Proteins 0.000 description 4
- YYPNNBPPDFTQFX-UHFFFAOYSA-N 2-thiophen-3-ylethanol Chemical compound OCCC=1C=CSC=1 YYPNNBPPDFTQFX-UHFFFAOYSA-N 0.000 description 4
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 4
- IFPAPBFCYGUMJZ-UHFFFAOYSA-N 3-methylidenepentan-1-ol Chemical compound CCC(=C)CCO IFPAPBFCYGUMJZ-UHFFFAOYSA-N 0.000 description 4
- QFXSWGXWZXSGLC-UHFFFAOYSA-N 3-methylpent-2-en-1-ol Chemical compound CCC(C)=CCO QFXSWGXWZXSGLC-UHFFFAOYSA-N 0.000 description 4
- WHOKGSBCDRFBBF-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]hept-1-ene Chemical compound C1C(C)CC=C2C(C)(C)C12 WHOKGSBCDRFBBF-UHFFFAOYSA-N 0.000 description 4
- 108030001841 4-hydroxybenzoate geranyltransferases Proteins 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 101800001241 Acetylglutamate kinase Proteins 0.000 description 4
- 108700021045 Acetylglutamate kinase Proteins 0.000 description 4
- 108010075293 Cannabidiolic acid synthase Proteins 0.000 description 4
- 102100027306 Carotenoid-cleaving dioxygenase, mitochondrial Human genes 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102100036158 Ceramide kinase Human genes 0.000 description 4
- 108010017573 Ceramide kinase Proteins 0.000 description 4
- 108030006282 Coumarin 8-geranyltransferases Proteins 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 4
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 4
- 102000016680 Dioxygenases Human genes 0.000 description 4
- 108010028143 Dioxygenases Proteins 0.000 description 4
- 102000053665 EC 2.7.2.- Human genes 0.000 description 4
- 108700036021 EC 2.7.2.- Proteins 0.000 description 4
- 108700034618 EC 2.7.2.10 Proteins 0.000 description 4
- 108700034617 EC 2.7.2.12 Proteins 0.000 description 4
- 108030003462 Exo-alpha-bergamotene synthases Proteins 0.000 description 4
- 102100026859 FAD-AMP lyase (cyclizing) Human genes 0.000 description 4
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 4
- 108030006723 Flaviolin linalyltransferases Proteins 0.000 description 4
- 108030006794 Fumigaclavine A dimethylallyltransferases Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 108030001631 Geranylgeranyl diphosphate synthases Proteins 0.000 description 4
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 4
- 108700023479 Glutamate 5-kinases Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108030006699 Homogentisate geranylgeranyltransferases Proteins 0.000 description 4
- 108010033079 Isopiperitenone Delta-isomerase Proteins 0.000 description 4
- PDSNLYSELAIEBU-UHFFFAOYSA-N Longifolene Chemical compound C1CCC(C)(C)C2C3CCC2C1(C)C3=C PDSNLYSELAIEBU-UHFFFAOYSA-N 0.000 description 4
- ZPUKHRHPJKNORC-UHFFFAOYSA-N Longifolene Natural products CC1(C)CCCC2(C)C3CCC1(C3)C2=C ZPUKHRHPJKNORC-UHFFFAOYSA-N 0.000 description 4
- 108010067749 Muconolactone Delta-isomerase Proteins 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 108030001803 Naringenin 8-dimethylallyltransferases Proteins 0.000 description 4
- 108030003742 Pantoate kinases Proteins 0.000 description 4
- 108010085387 Patchoulol synthase Proteins 0.000 description 4
- 108700023219 Phosphoglycerate kinases Proteins 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 101710173432 Phytoene synthase Proteins 0.000 description 4
- 108010057761 Polyenoic fatty acid isomerase Proteins 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 241000516658 Roseiflexus castenholzii Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 4
- 108030007080 Thiamine-phosphate kinases Proteins 0.000 description 4
- 108030003280 Trans-2,3-dihydro-3-hydroxyanthranilate isomerases Proteins 0.000 description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 4
- 108030001901 Trihydroxypterocarpan dimethylallyltransferases Proteins 0.000 description 4
- 108020000553 UMP kinase Proteins 0.000 description 4
- 101710100179 UMP-CMP kinase Proteins 0.000 description 4
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 description 4
- 108030006288 Umbelliferone 6-dimethylallyltransferases Proteins 0.000 description 4
- 108700024326 Undecaprenol kinases Proteins 0.000 description 4
- 108030003566 Valencene synthases Proteins 0.000 description 4
- 108010093991 Vinylacetyl-CoA Delta-isomerase Proteins 0.000 description 4
- 108030003503 Zingiberene synthases Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 108060000514 aromatic prenyltransferase Proteins 0.000 description 4
- 108010004523 aspulvinone dimethylallyltransferase Proteins 0.000 description 4
- 229940036350 bisabolol Drugs 0.000 description 4
- NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 4
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 4
- 229950011318 cannabidiol Drugs 0.000 description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- OOCCDEMITAIZTP-UHFFFAOYSA-N cinnamyl alcohol Chemical compound OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 4
- WTOYNNBCKUYIKC-UHFFFAOYSA-N dl-nootkatone Natural products C1CC(C(C)=C)CC2(C)C(C)CC(=O)C=C21 WTOYNNBCKUYIKC-UHFFFAOYSA-N 0.000 description 4
- 229960004242 dronabinol Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108010044215 ethanolamine kinase Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108060004506 lycopene beta-cyclase Proteins 0.000 description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 4
- SXFKFRRXJUJGSS-UHFFFAOYSA-N olivetolic acid Chemical compound CCCCCC1=CC(O)=CC(O)=C1C(O)=O SXFKFRRXJUJGSS-UHFFFAOYSA-N 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- GGHMUJBZYLPWFD-CUZKYEQNSA-N patchouli alcohol Chemical compound C1C[C@]2(C)[C@@]3(O)CC[C@H](C)[C@@H]2C[C@@H]1C3(C)C GGHMUJBZYLPWFD-CUZKYEQNSA-N 0.000 description 4
- LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical compound OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 4
- 108010001545 phytoene dehydrogenase Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- GGHMUJBZYLPWFD-UHFFFAOYSA-N rac-patchouli alcohol Natural products C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 description 4
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 108010073742 thiamin-diphosphate kinase Proteins 0.000 description 4
- WCTNXGFHEZQHDR-UHFFFAOYSA-N valencene Natural products C1CC(C)(C)C2(C)CC(C(=C)C)CCC2=C1 WCTNXGFHEZQHDR-UHFFFAOYSA-N 0.000 description 4
- 229930001895 zingiberene Natural products 0.000 description 4
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 4
- PDEQKAVEYSOLJX-YHYXMXQVSA-N α-santal-10-en-12-ol Chemical compound C1C2C3(C)C2CC1C3(C)CC/C=C(CO)/C PDEQKAVEYSOLJX-YHYXMXQVSA-N 0.000 description 4
- KWFJIXPIFLVMPM-UHFFFAOYSA-N α-santalene Chemical compound C1C2C3(C)C2CC1C3(C)CCC=C(C)C KWFJIXPIFLVMPM-UHFFFAOYSA-N 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- SIIVGPQREKVCOP-ONEGZZNKSA-N (e)-but-1-en-1-ol Chemical compound CC\C=C\O SIIVGPQREKVCOP-ONEGZZNKSA-N 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- BYDRTKVGBRTTIT-UHFFFAOYSA-N 2-methylprop-2-en-1-ol Chemical compound CC(=C)CO BYDRTKVGBRTTIT-UHFFFAOYSA-N 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- 241000219195 Arabidopsis thaliana Species 0.000 description 3
- 241000193419 Geobacillus kaustophilus Species 0.000 description 3
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 3
- 108700040132 Mevalonate kinases Proteins 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 3
- 102100037997 Squalene synthase Human genes 0.000 description 3
- 102100039081 Steroid Delta-isomerase Human genes 0.000 description 3
- 241000204673 Thermoplasma acidophilum Species 0.000 description 3
- 102000030766 Thiamin Pyrophosphokinase Human genes 0.000 description 3
- 108010001088 Thiamin pyrophosphokinase Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- QMZRXYCCCYYMHF-UHFFFAOYSA-N isopentenyl phosphate Chemical compound CC(=C)CCOP(O)(O)=O QMZRXYCCCYYMHF-UHFFFAOYSA-N 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000002678 mevalonate kinase Human genes 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- MQCJHQBRIPSIKA-UHFFFAOYSA-N prenyl phosphate Chemical compound CC(C)=CCOP(O)(O)=O MQCJHQBRIPSIKA-UHFFFAOYSA-N 0.000 description 3
- 229940048084 pyrophosphate Drugs 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 108010085346 steroid delta-isomerase Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- YMBFCQPIMVLNIU-UHFFFAOYSA-N trans-alpha-bergamotene Natural products C1C2C(CCC=C(C)C)(C)C1CC=C2C YMBFCQPIMVLNIU-UHFFFAOYSA-N 0.000 description 3
- 108030004879 (+)-delta-cadinene synthases Proteins 0.000 description 2
- DGZBGCMPRYFWFF-KKUMJFAQSA-N (+)-endo-beta-bergamotene Chemical compound C1[C@@H]2[C@](CCC=C(C)C)(C)[C@H]1CCC2=C DGZBGCMPRYFWFF-KKUMJFAQSA-N 0.000 description 2
- 108030004296 (+)-epi-alpha-bisabolol synthases Proteins 0.000 description 2
- YMBFCQPIMVLNIU-KKUMJFAQSA-N (-)-endo-alpha-bergamotene Chemical compound C1[C@@H]2[C@](CCC=C(C)C)(C)[C@H]1CC=C2C YMBFCQPIMVLNIU-KKUMJFAQSA-N 0.000 description 2
- 108030007131 (d)CMP kinases Proteins 0.000 description 2
- 108010026367 (deoxy)adenylate kinase Proteins 0.000 description 2
- 108030004093 1,8-cineole synthases Proteins 0.000 description 2
- OINNEUNVOZHBOX-QIRCYJPOSA-N 2-trans,6-trans,10-trans-geranylgeranyl diphosphate Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-QIRCYJPOSA-N 0.000 description 2
- MZAYLSDNFVNUOD-UHFFFAOYSA-N 3-methylbut-3-en-2-yl phosphono hydrogen phosphate Chemical compound CC(C(C)=C)OP(O)(OP(O)(O)=O)=O MZAYLSDNFVNUOD-UHFFFAOYSA-N 0.000 description 2
- 108030007077 3-phosphoglyceroyl-phosphate-polyphosphate phosphotransferases Proteins 0.000 description 2
- 108010042260 4-hydroxybenzoate polyprenyltransferase Proteins 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 108030006837 4-hydroxyphenylpyruvate 3-dimethylallyltransferases Proteins 0.000 description 2
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 2
- LOFHPLKGPULNQP-UHFFFAOYSA-N 4-methylpent-4-en-1-ol Chemical compound CC(=C)CCCO LOFHPLKGPULNQP-UHFFFAOYSA-N 0.000 description 2
- 108010038076 5-carboxymethyl-2-hydroxymuconate Delta-isomerase Proteins 0.000 description 2
- 108030007076 5-methyldeoxycytidine-5'-phosphate kinases Proteins 0.000 description 2
- 244000178606 Abies grandis Species 0.000 description 2
- 235000017894 Abies grandis Nutrition 0.000 description 2
- 241001165345 Acinetobacter baylyi Species 0.000 description 2
- 108030003464 Alpha-santalene synthases Proteins 0.000 description 2
- 235000018921 Artemisia spiciformis Nutrition 0.000 description 2
- 241000648485 Artemisia spiciformis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- 241000040345 Bacillus shackletonii Species 0.000 description 2
- 108030003466 Beta-santalene synthases Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000251535 Branchiostoma floridae Species 0.000 description 2
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 2
- JNRZNAGCSGWZMY-UHFFFAOYSA-N C(C(=O)C)(=O)OP(=O)=O Chemical compound C(C(=O)C)(=O)OP(=O)=O JNRZNAGCSGWZMY-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- XOBVPFHBUGISSX-SNAWJCMRSA-N CC(C)C(C)\C=C\O Chemical compound CC(C)C(C)\C=C\O XOBVPFHBUGISSX-SNAWJCMRSA-N 0.000 description 2
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 2
- 101000712615 Cannabis sativa Tetrahydrocannabinolic acid synthase Proteins 0.000 description 2
- 241000511343 Chondrostoma nasus Species 0.000 description 2
- 241000221751 Claviceps purpurea Species 0.000 description 2
- 108010078491 Diphosphoinositol-pentakisphosphate kinase Proteins 0.000 description 2
- 108030007154 Dolichyl-diphosphate-polyphosphate phosphotransferases Proteins 0.000 description 2
- 108700035838 EC 4.2.3.53 Proteins 0.000 description 2
- 108700035837 EC 4.2.3.54 Proteins 0.000 description 2
- 102100033166 Ethanolamine kinase 2 Human genes 0.000 description 2
- 108010043449 Farnesyl phosphate kinase Proteins 0.000 description 2
- 108030007078 Farnesyl-diphosphate kinases Proteins 0.000 description 2
- 101710198928 Gamma-glutamyl phosphate reductase Proteins 0.000 description 2
- 108030006811 Geranylpyrophosphate-olivetolic acid geranyltransferases Proteins 0.000 description 2
- 108010026318 Geranyltranstransferase Proteins 0.000 description 2
- 102000013404 Geranyltranstransferase Human genes 0.000 description 2
- 240000000047 Gossypium barbadense Species 0.000 description 2
- 235000009429 Gossypium barbadense Nutrition 0.000 description 2
- 108020004202 Guanylate Kinase Proteins 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 241000204933 Haloferax volcanii Species 0.000 description 2
- 108010012621 Inositol-hexakisphosphate kinase Proteins 0.000 description 2
- 150000000963 Kdo2-lipid A derivatives Chemical class 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108030001470 Lipid A phosphoethanolamine transferases Proteins 0.000 description 2
- 108030004940 Longifolene synthases Proteins 0.000 description 2
- 240000000894 Lupinus albus Species 0.000 description 2
- 235000010649 Lupinus albus Nutrition 0.000 description 2
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 2
- 241000203378 Methanococcus vannielii Species 0.000 description 2
- 241001532621 Methanosalsum zhilinae Species 0.000 description 2
- 108010011026 Nucleoside-triphosphate-adenylate kinase Proteins 0.000 description 2
- 108010016852 Orthophosphate Dikinase Pyruvate Proteins 0.000 description 2
- 241001621940 Parageobacillus caldoxylosilyticus Species 0.000 description 2
- 241000081271 Phaffia rhodozyma Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 241000195517 Rhizosolenia setigera Species 0.000 description 2
- 241000187561 Rhodococcus erythropolis Species 0.000 description 2
- 108030007153 Ribose 1,5-bisphosphate phosphokinases Proteins 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 241000589196 Sinorhizobium meliloti Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 2
- 108030001636 Squalene synthases Proteins 0.000 description 2
- 241000205091 Sulfolobus solfataricus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108030007079 Thiamine-diphosphate kinases Proteins 0.000 description 2
- 102100037357 Thymidylate kinase Human genes 0.000 description 2
- 241000700688 Trichoplax adhaerens Species 0.000 description 2
- 102100020797 UMP-CMP kinase Human genes 0.000 description 2
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 2
- 108030007083 UMP/CMP kinases Proteins 0.000 description 2
- 101710166980 Uridylate kinase Proteins 0.000 description 2
- 101710161108 [5-(aminomethyl)furan-3-yl]methyl phosphate kinase Proteins 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- DGZBGCMPRYFWFF-UHFFFAOYSA-N beta-trans-Bergamoten Natural products C1C2C(CCC=C(C)C)(C)C1CCC2=C DGZBGCMPRYFWFF-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 108010000742 dTMP kinase Proteins 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 108010049772 geranylgeranyl phosphate kinase Proteins 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 102000006638 guanylate kinase Human genes 0.000 description 2
- 108010006833 limonene-6-hydroxylase Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- KXFJZKUFXHWWAJ-UHFFFAOYSA-N p-hydroxybenzoylformic acid Natural products OC(=O)C(=O)C1=CC=C(O)C=C1 KXFJZKUFXHWWAJ-UHFFFAOYSA-N 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 108010006451 phosphomethylpyrimidine kinase Proteins 0.000 description 2
- 108010040557 polyphosphate AMP phosphotransferase Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 108010054126 retinoid isomerohydrolase Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GLWYBXPXOSKQAW-OALUTQOASA-N tryprostatin B Chemical compound N1C(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=C(CC=C(C)C)NC2=CC=CC=C21 GLWYBXPXOSKQAW-OALUTQOASA-N 0.000 description 2
- GLWYBXPXOSKQAW-UHFFFAOYSA-N tryptostatin B Natural products N1C(=O)C2CCCN2C(=O)C1CC1=C(CC=C(C)C)NC2=CC=CC=C21 GLWYBXPXOSKQAW-UHFFFAOYSA-N 0.000 description 2
- 108010062110 water dikinase pyruvate Proteins 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- GNWBLLYJQXKPIP-ZOGIJGBBSA-N (1s,3as,3bs,5ar,9ar,9bs,11as)-n,n-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1h-indeno[5,4-f]quinoline-1-carboxamide Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(CC)CC)[C@@]2(C)CC1 GNWBLLYJQXKPIP-ZOGIJGBBSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 1
- QVDTXNVYSHVCGW-UHFFFAOYSA-N 3-methylbut-1-en-1-ol Chemical class CC(C)C=CO QVDTXNVYSHVCGW-UHFFFAOYSA-N 0.000 description 1
- WCWLEIAMBPYRFJ-UHFFFAOYSA-N 3-methylbutyl dihydrogen phosphate Chemical compound CC(C)CCOP(O)(O)=O WCWLEIAMBPYRFJ-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100031082 Choline/ethanolamine kinase Human genes 0.000 description 1
- 101710147336 Choline/ethanolamine kinase Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000168022 Elaphurus davidianus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 102100029054 Homeobox protein notochord Human genes 0.000 description 1
- 101000634521 Homo sapiens Homeobox protein notochord Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001302035 Methanothermobacter Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000019337 Prenyltransferases Human genes 0.000 description 1
- 108050006837 Prenyltransferases Proteins 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229930000766 bergamotene Natural products 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229930003493 bisabolene Natural products 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002368 sesterterpene Natural products 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010087432 terpene synthase Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
- C12P5/007—Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/90—Protozoa ; Processes using protozoa
Definitions
- the invention relates to a process for isoprenoid production by an in-vitro synthetic platform involving at least the steps of phosphorylating a first hemiterpene alcohol with a first phosphate donor under catalysis of a first kinase thereby obtaining a first hemiterpene monophosphate and phosphorylating the latter with a second phosphate donor under catalysis of a second kinase thereby obtaining at least first hemiterpene diphosphate.
- the invention further relates to a composition comprising at least first hemiterpene diphosphate obtainable by the process according to the invention.
- isoprenoids including cannabinoids, terpenes and terpenoids, have gained great importance in a variety of industrially relevant applications for the production of pharmaceuticals, cosmetics, perfumes, flavors, animal feed supplements and nutraceuticals.
- terpenes and terpenoids may be obtained from natural sources i.e. by extraction.
- natural sources i.e. by extraction.
- a fundamental problem associated thereto regards the low availability, above all, due to the low amenability of such natural sources to large-scale production.
- terpenoids are largely derived from two major diphosphorylated building blocks: isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). Following their generation, such diphosphorylated building blocks may be subjected to sequential condensation under catalysis of specific prenyltransferases thereby resulting in geranyl pyrophosphate (GPP), famesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) which then may be converted to the more complex terpenoids under catalysis of appropriate terpene synthases. The resulting terpenoids may be then further functionalized either chemically or under enzymatic catalysis.
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- TMP terpene mini -path
- AP promiscuous acid phosphatase
- IPK isopentenyl phosphate kinase
- WO 2011/009132 A2 relates to methods and compositions pertaining to the synthesis of isoprenoid diphosphates by using selected enzymes (i.e. isopentyl monophosphate kinase (IMK)) and methods to identify amino acid substitutions within the IMKs which increase isoprenoid production rate.
- IMK isopentyl monophosphate kinase
- this method requires expensive starting materials such as isoprenoid diphosphate which direct impacts on the economic feasibility of the whole process.
- WO 2019/023192 Al relates to herbicide-detoxifying enzymes, compositions containing one or more of the enzymes, and plant seeds treated with the enzymes.
- WO 2019/232025 A2 relates to cells and cell-free systems for the conversion of isopentenols to isoprenoid precursors which are reacted with enzymes (choline kinase from S. cerevisiae) that phosphorylate short chain alcohol to produce the corresponding monophosphate, followed by phosphorylation of the latter to afford diphosphates upon reaction with a suitable enzyme (e.g. isopentenyl phosphate kinase (IPK)).
- IPK isopentenyl phosphate kinase
- IKI isopentenyl pyrophosphate isomerase
- IDI is also disclosed which is instrumental for the conversion of one or more synthetic precursors into the respective constitutional isomer.
- WO 2020/150340 Al discloses methods for preparing isoprenoid subunits, as well as methods of employing these isoprenoid subunits for the synthesis of isoprenoids.
- a primary alcohol is reacted with an enzyme performing a first phosphorylation such as a phosphatase that exhibits bidirectional activity, a single enzyme or a system involving two independent kinases (i.e. a first and second kinase), in the presence of ATP to generate the corresponding diphosphates.
- a first phosphorylation such as a phosphatase that exhibits bidirectional activity, a single enzyme or a system involving two independent kinases (i.e. a first and second kinase)
- PhoN a non-specific phosphatase from S. flexneri, shows a superior activity in the phosphorylation of DMAA/ISO.
- the processes of the prior art are not satisfactory in every respect and there is a demand for improved
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- a first aspect of the invention relates to a process for the preparation of a first hemiterpene diphosphate comprising the steps of:
- step (a2) phosphorylating the first hemiterpene monophosphate obtained in step (ai) with a second phosphate donor under catalysis of a second kinase thereby obtaining a first hemiterpene diphosphate and a second phosphate acceptor; wherein "terpene” encompasses terpenes as well as terpenoids according to IUPAC.
- terpene is preferably not limited to “terpenes” according to IUPAC, but is to be interpreted in a broader meaning to additionally also encompass “terpenoids” according to IUPAC.
- terpenoids are natural products and related compounds formally derived from isoprene units.
- terpenes contain oxygen in various functional groups. This class is subdivided according to the number of carbon atoms in the same manner as are terpenes.
- the skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group (see https://goldbook.iupac.org/terms/view/T06279).
- terpenes are pure hydrocarbons, whereas “terpenoids” contain oxygen in various functional groups.
- terpene in the nomenclature of compounds containing oxygen in various functional groups, such as “terpene alcohol”, which in accordance with IUPAC nomenclature, due to the presence of the alcohol as oxygen functional group, is not a terpene but a terpenoid according to IUPAC.
- terpene refers to both, the pure hydrocarbons (terpenes according to IUPAC) and the derivatives contain oxygen in various functional groups (terpenoids according to IUPAC).
- terpene preferably refers to a derivative containing oxygen in at least one of various functional groups.
- hemiterpene diphosphate is preferably to be interpreted as a terpene or a terpenoid according to IUPAC, more specifically as a hemiterpene or hemiterpenoid comprising up to five carbons atoms as well as two phosphorus atoms connected by an oxygen atom to give an P-O-P linkage.
- a hemiterpene diphosphate may for instance be obtained by reaction of pyrophosphoric acid (H4P2O7) with a hemiterpene alcohol, or analogously by reacting phosphoric acid (H3PO4) with a hemiterpene monophosphate.
- H4P2O7 pyrophosphoric acid
- H3PO4 phosphoric acid
- Step (ai) of the process according to the invention involves phosphorylation of a hemiterpene alcohol.
- a "hemiterpene alcohol” is preferably to be interpreted as a terpene or a terpenoid according to IUPAC, more specifically as a hemiterpene or hemiterpenoid comprising up to five carbons atoms as well as at least one alcoholic group within the hydrocarbon skeleton.
- Step (a2) of the process according to the invention involves phosphorylation of a hemiterpene monophosphate.
- a "hemiterpene monophosphate” is preferably to be interpreted as a terpene or a terpenoid according to IUPAC, more specifically as a hemiterpene or hemiterpenoid comprising up to five carbons atoms as well as one phosphate group.
- a hemiterpene monophosphate may for instance be obtained by reacting phosphoric acid (H3PO4) with a hemiterpene alcohol.
- phosphorylation refers to the attachment of a phosphate group to an organic molecule via a suitable mechanism for example by condensation, substitution or addition.
- Steps (ai) and (a2) of the process according to the invention involve phosphorylation under catalysis of a kinase.
- a "kinase” is preferably to be interpreted as an enzyme that catalyzes the transfer of phosphate groups from a phosphate donor to specific substrates.
- Steps (ai) and (a2) of the process according to the invention involve phosphorylation with a phosphate donor.
- a "phosphate donor” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit during the course of a reaction.
- Steps (ai) and (a2) of the process according to the invention involve phosphorylation with a phosphate donor obtaining a phosphate acceptor.
- a "phosphate acceptor" is preferably to be interpreted as a chemical species deriving from a dephosphorylation reaction of the corresponding phosphate donor, i.e. presenting at least one phosphate unit less than the corresponding phosphate donor.
- the phosphate acceptor is preferably characterized by a molecular structure amenable to undergo addition of a phosphate unit thereby re- pristinating the corresponding phosphate donor.
- (deoxy) shall preferably be understood as being entirely optional, i.e. covering both deoxy and non-deoxy variants of the same chemical substance.
- conversion is preferably to be interpreted as the ratios between the molar amount of consumed reactant and the molar amount of reactant initially employed in the reaction.
- first kinase is preferably to be interpreted as an enzyme capable of catalyzing the monophosphorylation of an alcohol, said alcohol being preferably a hemiterpene alcohol, and even more preferably isoprenol and/or prenol.
- the first kinase is an enzyme capable of catalyzing the transfer of a phosphate group selected from the group consisting of:
- - phosphotransferase with alcohol group as acceptor preferably selected from the group consisting of ethanolamine kinase (EC 2.7.1.82), amide-alcohol kinase, ceramide kinase (EC 2.7.1.138), pantoate kinase (EC 2.7.1.169), undecaprenol kinase (EC 2.7.1.66), choline kinase (EC 2.7.1.32), glycerol kinase (EC 2.7.1.30), glycerone kinase (EC 2.7.1.29), mevalonate kinase (EC 2.7.1.30), and hydrox- yethylthiazole kinase (EC 2.7.1.50);
- phosphotransferases with a phosphate group as an acceptor EC 2.7.4; preferably selected from the group consisting of polyphosphate kinase, phosphomevalonate kinase, adenylate kinase, nucleosidephosphate kinase, deoxycytidylate kinase, nucleoside-diphosphate kinase, phosphomethylpyrimidine kinase, guanylate kinase, dTMP kinase, nucleoside-triphosphate-adenylate kinase, (deoxy) adenylate kinase, T2-induced deoxynucleotide kinase, (deoxy) nucleoside-phosphate kinase, UMP/CMP kinase, thiamine-diphosphate kinase, thiamine-phosphate kinase, 3-phosphoglyceroyl--phosphat
- - phosphotransferases with a carboxy group as acceptor EC 2.7.2: acetate kinase (EC 2.7.2.1), acetate kinase (diphosphate), (EC2.7.2.12), phosphoglycerate kinase (GTP) (EC2.7.2.10), glutamate 5-ki- nase (EC 2.7.2.11), glutamate 1-kinase (EC 2.7.2.13), branched-chain-fatty-acid kinase (EC 2.7.2.14), propionate kinase (EC 2.7.2.15), 2-phosphoglycerate kinase (EC 2.7.2.
- [amino group carrier protein] -L-2 -aminoadipate 6-kinase (EC 2.7.2.17), carbamate kinase (EC 2.7.2.2), phosphoglycerate kinase (EC 2.7.2.3), aspartate kinase (EC 2.7.2.4), formate kinase( EC 2.7.2.6), (EC2.7.2.6), butyrate kinase (EC 2.7.2.7), acetylglutamate kinase (EC 2.7.2.8).
- the first kinase is a hydroxyethylthiazole kinase from Escherichia coli (EC 2.7. 1.50).
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the first kinase is a choline kinase from Plasmodium falciparum (PfCK) (EC 2.7.1.32).
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the first kinase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:2.
- the first kinase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the first kinase according to the invention may essentially consist of said amino acid sequence.
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-terminus and/or at the C-terminus of said subsequence. Such extension may be advantageous, for example, when the first kinase is to be immobilized on a solid support, e.g. for purification purposes.
- step (ai) is performed in a liquid reaction medium and the first kinase is employed in a concentration of at least 0.0001 mg/ml.
- step (ai) is performed in a liquid reaction medium and the first kinase is employed in a concentration of at most 1000 mg/ml; preferably at most 100 mg/ml, more preferably at most 10 mg/ml.
- the first "hemiterpene alcohol” is preferably to be interpreted as a terpene or a terpenoid according to IUPAC comprising up to five carbons atoms as well as at least one alcoholic group within the hydrocarbon skeleton.
- the first hemiterpene alcohol is preferably selected from the group consisting of isoprenol, 3-methyl-3-buten-2-ol, tiglic alcohol, angelicic alcohol, senecioic alcohol and isovaleric alcohol, 2-Methyl-2-propen-l-ol, 3 -methylene- 1 -pentanol, 2-hexen-l-ol, 4-penten-l-ol, 3 -thiopheneethanol, 4-methyl-4-penten-l-ol, 2-(Z)-hexen-l-ol, 2-butyn-l-ol, 3 -furanmethanol, 3-buten-l-ol, (2E)-bu- ten-l-ol, 3-methyl-2-penten-l-ol, 3-butyn-l-ol, 3,4-dimethyl-(2£)-penten-l-ol, (2E)-butene-2-methyl- 1,4-dio
- the first hemiterpene alcohol is isoprenol or prenol, and even more preferably isoprenol.
- the first hemiterpene alcohol is employed in a concentration of at least 0.1 mM; preferably of at least 0.5 mM, more preferably of at least 1.0 mM.
- step (ai) is performed in a liquid reaction medium and the first hemiterpene alcohol is employed in a concentration of at most 2000 mM; preferably at most 1500 mM, more preferably at most 1000 mM.
- the "first phosphate donor” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit during the course of a reaction.
- the first phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably the first phosphate donor is a nucleoside mono- or polyphosphate preferably selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glu- cose-6-phosphate, fructose- 1,6-bisphosphate, or 3 -phosphoglycerate.
- the first phosphate donor is a triphosphorylated conjugate of a ribose or a deoxyribose with a nucleobase selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil and even more preferably of adenosine.
- the first phosphate donor is adenosine triphosphate (ATP).
- ATP adenosine triphosphate
- step (ai) is preferably performed in a liquid reaction medium and the first phosphate donor is employed in a concentration of at least 0.001 mM; preferably at least 0.005 mM, more preferably at least 0.01 mM.
- step (ai) is performed in a liquid reaction medium and the first phosphate donor is employed in a concentration of at most 1000 mM; preferably at most 100 mM, more preferably at most 10 mM.
- step (a2) of the process according to the invention the first hemiterpene monophosphate obtained from step (ai) is reacted with a second phosphate donor under catalysis of a second kinase thereby obtaining a first hemiterpene diphosphate and a second phosphate acceptor.
- the "second kinase” preferably refers to an enzyme capable of catalyzing the phosphorylation of a mono- or polyphosphorylated alcohol, preferably of a mono- or polyphosphorylated hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isopentenyl monophosphate and/or dimethylallyl monophosphate.
- the second kinase in an enzyme capable of catalyzing the transfer of a phosphate group, such as phosphotransferase with a phosphate group as acceptor.
- the second kinase in an enzyme selected from the group consisting of polyphosphate kinase (EC 2.7.4.
- phosphomevalonate kinase (EC 2.7.4.2), adenylate kinase (EC 2.7.4.3), nucleoside-phosphate kinase (EC 2.7.4.4), thiamine-diphosphate kinase (EC 2.7.4.15), thi- amone-phosphate kinase (EC 2.7.4.16), famesyl-diphosphate kinase (EC 2.7.4.18), isopentenyl phosphate kinase (EC 2.7.4.26), and famesyl phosphate kinase (EC 2.7.4.32), phosphotransferases with a carboxy group as acceptor (EC 2.7.2): acetate kinase (EC 2.7.2.1), acetate kinase (diphosphate), (EC2.7.2.12), phosphoglycerate kinase (GTP) (EC2.7.2.10), glutamate 5-kinase (EC 2.7.2.
- [amino group carrier protein] -L-2 -aminoadipate 6- kinase (EC 2.7.2.17), carbamate kinase (EC 2.7.2.2), phosphoglycerate kinase (EC 2.7.2.3), aspartate kinase (EC 2.7.2.4), formate kinase (EC 2.7.2.6), (EC2.7.2.6), butyrate kinase (EC 2.7.2.7), acetylglutamate kinase (EC 2.7.2.8), preferably a isopentenyl phosphate kinase (EC 2.7.4.26).
- said isopentenyl phosphate kinase is selected from an organism selected from the group consisting of Arabidopsis thaliana, Branchiostoma floridae, Meth- anolobus tindarius,Methanococcus vannielii, aus Roseiflexus castenholzii, Thermoplasma acidophilum, Methanothermobacter thermoautotropicus , Methanocaldococcus jannaschii, Haloferax volcanii, Sul- folobus solfataricus, Trichoplax adhaerens, or Methanosalsum zhilinae.
- the second kinase is a isopentenyl phosphate kinase from Roseiflexus castenholzii.
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the second kinase is a isopentenyl phosphate kinase from Methanol- obus tindarius.
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61 %, or at least 62%, or at least 63 %, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the second kinase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of the first kinase, SEQ ID NO:3 or SEQ ID NO:4.
- the second kinase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the second kinase according to the invention may essentially consist of said amino acid sequence.
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-ter- minus and/or at the C-terminus of said subsequence.
- Such extension may be advantageous, for example, when the second kinase is to be immobilized on a solid support, e.g. for purification purposes.
- step (ai) is performed in a liquid reaction medium and the second kinase is employed in a concentration of at least 0.0001 mg/ml.
- step (ai) is performed in a liquid reaction medium and the second kinase is employed in a concentration of at most 1000 mg/ml; preferably at most 100 mg/ml, most preferably at most 10 mg/ml.
- the "second phosphate donor” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit during the course of a reaction.
- the second phosphate donor preferably belongs to the same chemical category as the first phosphate donor, i.e. organic or inorganic monophosphate or polyphosphate, and is capable of donating a phosphate unit during the course of a reaction.
- the second phosphate donor may not substantially differ from the first phosphate donor and preferably be a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, or 3 -phosphoglycerate.
- the second phosphate donor is the same as the first phosphate donor.
- the second phosphate donor is a triphosphorylated conjugate of a ribose or a deoxyribose with a nucleobase selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil and preferably of adenosine.
- this second phosphate donor is adenosine triphosphate.
- step (a2) is preferably performed in a liquid reaction medium and the second phosphate donor is employed in a concentration of at least 0.001 mM; preferably at least 0.005 mM, most preferably at least 0.1 mM.
- the second phosphate donor substantially differs from the first phosphate donor i.e. it has different molecular weights.
- the second phosphate donor and the first phosphate donor might differ by at one methine group.
- the second phosphate donor and the first phosphate donor differ by at most one methine group.
- step (a2) is performed in a liquid reaction medium and the second phosphate donor is employed in a concentration of at most 1000 mM; preferably at most 100 mM, most preferably at most 10 mM.
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least
- the first hemiterpene alcohol is isoprenol
- the first and second phosphate donor is adenosine triphosphate
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- Another aspect of the invention relates to a process for the preparation of a monoterpene diphosphate comprising the process for the preparation of a first hemiterpene diphosphate according to the invention as described above.
- the process additionally comprises the steps of:
- step (b) linking the first hemiterpene diphosphate obtained in step (as) with the second hemiterpene diphosphate provided in step (as) under catalysis of a monoterpene diphosphate synthase thereby obtaining the monoterpene diphosphate.
- Step (b) of the process according to the invention involves linking under catalysis of a monoterpene diphosphate synthase.
- the "monoterpene diphosphate” synthase is preferably an enzyme capable of catalyzing the condensation of one unit of the first hemiterpene diphosphate obtained in step (a2) with one unit of the second hemiterpene diphosphate provided in step (as).
- the monoterpene diphosphate synthase is a geranyl diphosphate synthase (GPPS) (EC 2.5. 1.1) and/or the monoterpene diphosphate is a geranyl diphosphate (GPP).
- GPPS geranyl diphosphate synthase
- GPP geranyl diphosphate
- the second hemiterpene diphosphate is obtained in step (a2) and/or in step (ai).
- the process may preferably entail performing step (as) as sub-step of steps (ai) and/or (a2) in an overall setting in which the second hemiterpene diphosphate is obtained concomitantly with the first hemiterpene monophosphate or diphosphate during the phosphorylation of the corresponding first hemiterpene alcohol or first hemiterpene monophosphate respectively, either in the same or in separate reaction environments.
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the monoterpene diphosphate is geranyl pyrophosphate (GPP); and/or
- the monoterpene diphosphate synthase is a geranyl diphosphate synthase (GPPS) belonging to EC 2.5. 1.1.
- GPPS geranyl diphosphate synthase
- Another aspect of the invention relates to a process for the preparation of a sesquiterpene diphosphate comprising
- the process additionally comprises the steps of:
- step (c) linking the first hemiterpene diphosphate obtained in step (a2) with the second hemiterpene diphosphate provided in step (as) under catalysis of a sesquiterpene diphosphate synthase thereby obtaining the sesquiterpene diphosphate.
- a "sesquiterpene diphosphate" is preferably to be interpreted as a terpene or a terpenoid according to IUPAC comprising up to fifteen carbons atoms as well as two phosphorus atoms connected by an oxygen atom to give an P-O-P linkage.
- Step (c) of the process according to the invention involves linking under catalysis of a sesquiterpene diphosphate synthase.
- the "sesquiterpene diphosphate synthase” is preferably an enzyme capable of catalyzing the sequential condensation of one or more units of the first hemiterpene diphosphate obtained in step (a2) with one unit of the second hemiterpene diphosphate provided in step (as).
- the second hemiterpene diphosphate may be obtained in step (as) and/or in step (ai).
- the process may preferably entail performing step (as) as sub-step of steps (ai) and/or (as) in an overall setting in which the second hemiterpene diphosphate is obtained concomitantly with the first hemiterpene monophosphate or diphosphate during the phosphorylation of the corresponding first hemiterpene alcohol or first hemiterpene monophosphate respectively, either in the same or in separate reaction environments.
- the sesquiterpene diphosphate synthase is a famesyl diphosphate synthase (FPPS) (EC 2.5.1.10).
- FPPS famesyl diphosphate synthase
- the sesquiterpene diphosphate synthase is preferably an FPPS from an organismus selected from the group consisting of Geobacillus stearothermophilus, Bos Taurus, Gallus gallus, Pseudomonas aeruginosa, Rhizosolenia setigera, Ricinus communis, Lupinus albus, Homo sapiens, Artemisia spiciformi or Abies grandis.
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and
- the sesquiterpene diphosphate synthase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NOTO, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14.
- SEQ ID NO:5 amino acid sequence with a defined identity to the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NOTO, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14.
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-terminus and/or at the C-terminus of said subsequence.
- extension may be advantageous, for example, when the sesquiterpene diphosphate synthase is to be immobilized on a solid support, e.g. for purification purposes.
- the sesquiterpene diphosphate is famesyl diphosphate (FPP).
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the sesquiterpene diphosphate is famesyl pyrophosphate (FPP); and/or
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- Another aspect of the invention relates to a process for the preparation of a diterpene diphosphate comprising
- the process additionally comprises the steps of:
- step (d) linking the first hemiterpene diphosphate obtained in step (as) with the second hemiterpene diphosphate provided in step (as) under catalysis of a diterpene diphosphate synthase thereby obtaining the diterpene diphosphate.
- a “diterpene diphosphate” is preferably to be interpreted as a terpene or a terpenoid according to IUPAC comprising up to twenty carbons atoms as well as two phosphorus atoms connected by an oxygen atom to give an P-O-P linkage.
- Step (d) of the process according to the invention involves linking under catalysis of a diterpene diphosphate synthase.
- the "sesquiterpene diphosphate synthase” is preferably to be interpreted as an enzyme capable of catalyzing the sequential condensation of one or more units of the first hemiterpene diphosphate obtained in step (a2) with one unit of the second hemiterpene diphosphate provided in step (as).
- the second hemiterpene diphosphate may be obtained in step (a2) and/or in step (ai).
- the process may preferably entail performing step (as) as sub-step of steps (ai) and/or (as) in an overall setting in which the second hemiterpene diphosphate is obtained concomitantly with the first hemiterpene monophosphate or diphosphate during the phosphorylation of the corresponding first hemiterpene alcohol or first hemiterpene monophosphate respectively, either in the same or in separate reaction environments.
- the diterpene diphosphate synthase is a geranylgeranyl diphosphate synthase (GPPS) (EC 2.5.1.29).
- GPPS geranylgeranyl diphosphate synthase
- the diterpene diphosphate is geranylgeranyl diphosphate (GGPP).
- the process of the invention is characterized in that:
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the diterpene diphosphate is geranylgeranyl pyrophosphate (GGPP); and/or
- the diterpene diphosphate synthase is a geranylgeranyl diphosphate synthase (GPPS) belonging to EC 2.5.1.29.
- GPPS geranylgeranyl diphosphate synthase
- Another aspect of the invention relates to a process for the preparation of a tetraterpene comprising
- the process additionally comprises the step of:
- tetraterpene is preferably to be interpreted as a terpene or a terpenoid according to IUPAC comprising up to forty carbons atoms as well as two phosphorus atoms connected by an oxygen atom to give an P-O-P linkage.
- Step (e) of the process according to the invention involves linking under catalysis of a tetraterpene synthase.
- the "tetraterpene synthase” is preferably an enzyme capable of catalyzing the sequential condensation of two or more units of the diterpene diphosphate obtained in step (d).
- the tetraterpene synthase is a phytoene synthase (EC 2.5.1.32).
- the tetraterpene is phytoene.
- the process is characterized in that:
- the tetraterpene is phytoene
- the tetraterpene synthase is a phytoene synthase belonging to EC 2.5.1.32.
- (B) a monoterpene diphosphate (preferably encompassing steps (ai), (a2), (as), and (b));
- (C) a sesquiterpene diphosphate (preferably encompassing steps (ai), (a2), (as), and (c));
- step (as) are described, that analogously apply to any of the above processes (B) through (E).
- step (as) comprises the sub-steps of:
- step (as.2) phosphorylating the second hemiterpene monophosphate obtained in step (as.i) with a fourth phosphate donor under catalysis of a fourth kinase thereby obtaining the second hemiterpene diphosphate and a fourth phosphate acceptor.
- first phosphate acceptor preferably to be interpreted as a chemical species deriving from a dephosphorylation reaction of the corresponding phosphate donor, i.e. presenting at least one phosphate unit less than it.
- the first, second, third or fourth phosphate acceptor is preferably characterized by a molecular structure amenable to undergo addition of a phosphate unit thereby divulgtinating the corresponding phosphate donor.
- the "second hemiterpene alcohol” is preferably to be interpreted as a terpene or a terpenoid according to IUPAC comprising up to five carbons atoms as well as at least one alcoholic group within the hydrocarbon skeleton.
- the second hemiterpene alcohol is a constitutional isomer of the first hemiterpene alcohol.
- substitutional isomer has the same meaning as it would be understood by a skilled artesian in the art i.e. a molecule presenting the same molecular formula of a parent molecule, however in a different special arrangement.
- the second hemiterpene alcohol is selected from the group consisting of isoprenol, 3-methyl-3-buten-2-ol, tiglic alcohol, angelicic alcohol, senecioic alcohol and isovaleric alcohol, 2-Me- thyl-2-propen-l-ol, 3 -methylene- 1 -pentanol, 2-hexen-l-ol, 4-penten-l-ol, 3 -thiopheneethanol, 4-me- thyl-4-penten-l-ol, 2-(Z)-hexen-l-ol, 2-butyn-l-ol, 3 -furanmethanol, 3-buten-l-ol, (2E)-buten-l-ol, 3- methyl-2-penten-l-ol, 3-butyn-l-ol, 3,4-dimethyl-(2£)-penten-l-ol, (2E)-butene-2 -methyl-
- the second hemiterpene alcohol is isoprenol or prenol, and most preferably prenol.
- the second hemiterpene alcohol is employed in a concentration of at least 0. 1 mM; preferably of at least 0.5 mM, most preferably of at least 1.0 mM.
- the second hemiterpene alcohol is employed in a concentration of at most 2000 mM; preferably at most 1500 mM, most preferably at most 1000 mM.
- the "third kinase” is preferably to be interpreted as an enzyme capable of catalyzing the phosphorylation of an alcohol, said alcohol being preferably a hemiterpene alcohol, and even more preferably isoprenol and/or prenol.
- the third kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the third kinase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of the first kinase, second kinase, or SEQ ID NO: 1.
- the third kinase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the third kinase according to the invention may essentially consist of said amino acid sequence.
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-terminus and/or at the C-terminus of said subsequence. Such extension may be advantageous, for example, when the third kinase is to be immobilized on a solid support, e.g. for purification purposes.
- the "fourth kinase” preferably refers to an enzyme capable of catalyzing the phosphorylation of a mono- or polyphosphorylated alcohol, preferably of a mono- or polyphosphorylated hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isopentenyl monophosphate and/or dimethylallyl monophosphate.
- the fourth kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- the fourth kinase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of the first kinase, second kinase, third kinase, or SEQ ID NO:3.
- the fourth kinase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the fourth kinase according to the invention may essentially consist of said amino acid sequence.
- said overall amino acid sequence may be extended, i.e.
- Such extension may be advantageous, for example, when the fourth kinase is to be immobilized on a solid support, e.g. for purification purposes.
- the "third phosphate donor” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit during the course of a reaction.
- the third phosphate donor preferably belongs to the same chemical category as the first or second phosphate donor, i.e. organic or inorganic monophosphate or polyphosphate, and is capable of donating a phosphate unit during the course of a reaction.
- the third phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the third phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phos- phate, fructose- 1,6-bisphosphate, and 3 -phosphoglycerate.
- the third phosphate donor has the same molecular structure as the first and /or second phosphate donor.
- the "fourth phosphate donor” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit during the course of a reaction.
- the fourth phosphate donor preferably belongs to the same chemical category as the first, second or third phosphate donor, i.e. organic or inorganic monophosphate or polyphosphate, and is capable of donating a phosphate unit during the course of a reaction.
- the fourth phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the first phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phos- phate, fructose- 1,6-bisphosphate, 3 -phosphoglycerate.
- the fourth phosphate donor has the same molecular structure as the first and second and/or third phosphate donor.
- the molar ratio of the first hemiterpene alcohol relative to second hemiterpene alcohol is at least 1: 10, or at least 1:2, or preferably at least 1: 1, or most preferably at least 2: 1 or 3: 1.
- the molar ratio of the first hemiterpene alcohol relative second hemiterpene alcohol is at most 100: 1; preferably at most 10: 1 or at most 5: 1, or preferably at most 3: 1.
- steps (ai), (a2), (as.i), (a-, 2) is repeated at least once;
- steps (ai), (a2), (as.i), (as.2) are performed in a single reactor;
- step (as) comprises the substep of
- an "isomerase” is preferably to be interpreted as an enzyme capable of altering the isomeric structure of a given initial isomeric substrate to afford a different isomeric substrate presenting the same molecular formula as compared with the initial substrate and different structural arrangement.
- the isomerase is selected from the group consisting of steroid delta isomerase (EC 5.3.3.1), vinylacetyl-CoA delta isomerase (EC 5.3.3.3), muconolactone delta-isomerase (EC 5.3.3.4), 5- carboxymethyl-2-ydroxymuconate delta isomerase (EC 5.3.3.10), isopiperitenone delta-isomerase (EC 5.3.3.11), polyenoic fatty acid isomerase (EC 5.3.3.13), trans-2,3-dihydro-3-hydroxyanthranilate isomerase (EC 5.3.3.17), lutein isomerase (5.3.3.22) and isopentenyl diphosphate isomerase (EC 5.3.3.2) and even more preferably the isomerase is a isopentenyl diphosphate isomerases (EC 5.3.3.2).
- steroid delta isomerase EC 3.1
- vinylacetyl-CoA delta isomerase EC 5.3.3.3
- muconolactone delta-isomerase
- the isomerase is a isopentenyl diphosphate isomerase from Schizosaccharomyces pombe, Claviceps purpurea, Phaffia rhodozyma, Homo sapiens, Sus scrofa, Gallus gallus, Solanum lycopersicum, Haematococcus lacustris, Gossypium barbadense, Escherichia coli, or Saccharomyces cerevisiae.
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 90%, or at least 9
- the Isomerase according to the invention comprises such an amino acid sequence with a defined identity to the amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24 SEQ ID NO:25.
- SEQ ID NO: 15 SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24 SEQ ID NO:25.
- the Isomerase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the Isomerase according to the invention may essentially consist of said amino acid sequence.
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-terminus and/or at the C-terminus of said subsequence.
- extension may be advantageous, for example, when the Isomerase is to be immobilized on a solid support, e.g. for purification purposes.
- the second hemiterpene diphosphate is selected from the group consisting of isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), 3-methyl-3-buten- 2-ol diphosphate, tiglic alcohol diphosphate, angelicic alcohol diphosphate, senecioic alcohol diphosphate and isovaleric alcohol diphosphate.
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- 3-methyl-3-buten- 2-ol diphosphate 3-methyl-3-buten- 2-ol diphosphate
- tiglic alcohol diphosphate tiglic alcohol diphosphate
- angelicic alcohol diphosphate senecioic alcohol diphosphate
- isovaleric alcohol diphosphate isovaleric alcohol diphosphate.
- the second hemiterpene diphosphate is a structural isomer; preferably a constitutional isomer of the first hemiterpene diphosphate.
- the second hemiterpene diphosphate is isopentenyl pyrophosphate (IPP) or dimethylallyl pyrophosphate (DMAPP).
- the second hemiterpene diphosphate is dimethylallyl pyrophosphate (DMAPP).
- the processes (A) through (E) according to the invention are characterized in that: - at least steps (ai) and (a2) are performed simultaneously; and/or
- steps (ai), (a2), (as.i), (as.2), (as s) is repeated at least once;
- steps (ai), (a2), (as.i), (as.2), (as s) are performed in a single reactor;
- steps (ai) and (a ,). are performed simultaneously;
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- the first hemiterpene alcohol is isoprenol
- the first, second, third and fourth phosphate donor is adenosine triphosphate
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- step (as) comprises the sub-steps of:
- the isomerase is a isopentenyl diphosphate isomerases an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the second hemiterpene diphosphate is dimethylallyl pyrophosphate (DMAPP); and/or
- the third phosphate donor and fourth phosphate donor are adenosine triphosphate.
- any of the processes (A) to ( E) and all their preferred embodiments as described above take place at a temperature of 2.0 °C to 99.5 °C, or 3.0°C to 95.0°C, or 4.0°C to 90.0°C, or 5.0°C to 85.0°C, or 15.0°C to 80.0°C, or 25.0°C to 75.0°C, or 28.0°C to 75.0°C, or 30.0°C to 60.0°C, or 33.0°C to 50.0°C, or 35.0°C to 45.0°C.
- any of the processes (A) to ( E) and all their preferred embodiments as described above take place in a liquid reaction medium, wherein said liquid reaction medium is characterized by a pH in the range of 5.0 to 8.5, or 5.3 to 8.5, or 5.5 to 8.5, or 5.8 to 8.5, or 6.0 to 8.5, or 6.4 to 8.5, or 6.6 to 8.5, or 6.9 to 8.5, 7.5 to 8.5, or 8.0 to 8.5.
- the process additionally comprises the step of:
- step (f) reacting a monoterpene diphosphate obtained in step (b) under catalysis of a monoterpene synthase thereby obtaining the monoterpene.
- the "monoterpene synthase” is preferably to be interpreted as an enzyme capable of catalyzing the rearrangement and/or cyclization of GPP into a monoterpene i.e. an organic compound comprising up to 10 carbon atoms.
- the monoterpene synthase is a an selected from the group consisting of squalensyn- thase (EC 2.5.1.21), 1,8-cineol synthase, (EC 4.2.3.108), (-)-sabinene synthase (EC 4.2.3.109), (+)-sab- inene synthase (EC 4.2.3.110), 5-carene-synthase (EC 4.2.3.107) and (R)-limonene synthase (EC 4.2.3.20), preferably wherein the monoterpene synthase is (-)-sabinene synthase (EC 4.2.3.109), (+)- sabinene synthase (EC 4.2.3.110), 5-carene-synthase (EC 4.2.3.107).
- squalensyn- thase EC 2.5.1.21
- 1,8-cineol synthase EC 4.2.3.108
- the monoterpene is selected from the group consisting of squalen 1,8-cineol, (-)- sabinene, (+)-sabinene, 5-carene and (R)-limonene, preferably wherein the monoterpene is squalen, (-)- sabinene, (+)-sabinene or 5-3-carene.
- Another aspect of the invention relates to a process for the preparation of carvone comprising the process for the preparation of a monoterpene, particularly for the preparation of (R)-limonene, according to the invention as described above.
- step (gi) reacting (R)-limonene obtained in step (f) under catalysis of a Limonene-6-hydroxylase (EC 1.14.13.48) thereby obtaining carvenol;
- the process according to the invention is characterized in that:
- steps (gi) or (g 2 ) are repeated at least once; and/or at least one of steps (gi) or (g 2 ) is performed in a single reactor; and/or steps (gi) or (g 2 ) are performed simultaneously.
- Another aspect of the invention relates to a process for the preparation of a cannanbinoide comprising the process for the preparation of a monoterpene diphosphate, particularly for the preparation of GPP according to the invention as described above.
- the process additionally comprises the step of:
- step (hi) reacting a monoterpene diphosphate, particularly GPP, obtained in step (b) with an olivetolic acid under catalysis of an aromatic prenyltransferase thereby obtaining cannabigerolic acid;
- CBDA cannabidiol
- THC tetrahydrocannabinol
- the aromatic prenyltransferase is a an selected from the group consisting of aspul- vinone dimethylallyltransferase (EC 2.5.1.35), trihydroxypterocarpan dimethylallyltransferase (EC 2.5.1.36), 4-hydroxybenzoic acid oligoprenyltransferase (EC 2.5.1.39), naringenin 8-dimethylallyltrans- ferase (EC 2.5.1.70), 4-hydroxybenzoate geranyltransferase (EC 2.5.1.93), fumigaclavine A dimethylallyltransferase (EC 2.5.1.100), geranylpyrophosphate :olivetolate geranyltransferase (EC 2.5.1.102), 4- hydroxyphenylpyruvate: dimethylallyl transferase (EC 2.5.1.111), homogentisate geranylgeranyltransferase (EC 2.5.1.116), flaviolin linalyltransfera
- the process according to the invention is characterized in that:
- steps (hi) (h 2 ) or (h ) is repeated at least once;
- steps (hi) (h 2 ) or (ha) is performed in a single reactor;
- Another aspect of the invention relates to a process for the preparation of a sesquiterpene comprising the process for the preparation of a sesquiterpene diphosphate according to the invention as described above. [0182] In this context, it is preferred that, besides steps (as) and (c) leading to the sesquiterpene diphosphate according to the invention as described above, the process additionally comprises the step of:
- step (i) reacting a sesquiterpene diphosphate obtained in step (c) under catalysis of a sesquiterpene synthase thereby obtaining the sesquiterpene.
- the sesquiterpene synthase is an enzyme capable of catalyzing the rearrangement and/or cyclization of FPP into a sesquiterpene i.e. an organic compound comprising up to 15 carbon atoms, preferably wherein the sesquiterpene synthase is a an enzyme selected from the group consisting of valencene synthase (EC 4.2.3.73), a-bisabolol-synthase (EC 4.2.3.138), (S)-beta-bisabolene synthase (EC 4.2.3.55), patchoulol synthase (EC 4.2.3.70), [3-elemene synthase (EC 4.2.3.x), 5-cadinene synthase (EC 4.2.3.13), (+)-endo-beta-bergamotene synthase (EC 4.2.3.53), (-)-endo-alpha-bergamo- tene synthase (EC 4.2.
- the sesquiterpene is selected from the group consisting of valencene, a-bisabolol, [3- bisabolene, patchoulol, [3-elemene, 5-cadinene, a-trans-bergamotene, [3-cis-bergamotene, [3-trans-berga- motene, zingiberene, longifolene, a-santalene, [3-santalene.
- Another aspect of the invention relates to a process for the preparation of sesquiterpenoid comprising the process for the preparation of a sesquiterpene according to the invention as described above.
- step (i) leading to the sesquiterpene the process additionally comprises the step of:
- step (j) reacting the sesquiterpene obtained in step (i) under catalysis of a monooxygenase (EC 1. 14.x.x) thereby obtaining sesquiterpenoid.
- the sesquiterpenoid is selected from the group consisting of nootkatone, hemandul- cin, a-santalol, [3-santalol.
- Another aspect of the invention relates to a process for the preparation of famesol comprising the process for the preparation of a sesquiterpene diphosphate, particularly for the preparation of FPP, according to the invention as described above.
- the process additionally comprises the step of: (k) reacting a sesquiterpene diphosphate, particularly FPP, obtained in step (c) under catalysis of a FPP-diphosphatase thereby obtaining farnesol.
- the FPP-diphosphatase is a phosphatase belonging to EC 3.6.1.x and/or EC 3.1.3.x.
- Another aspect of the invention relates to a process for the preparation of a sclareol comprising the process for the preparation of a diterpene diphosphate, particularly for the preparation of GGPP, according to the invention as described above.
- the process additionally comprises the step of:
- step (h) reacting a diterpene diphosphate, particularly GGPP obtained in step (d) under catalysis of a lab- denediol synthase (EC 4.2.1.133) thereby obtaining the labdenediol diphosphate (LDPP); and
- step (h) reacting labdenediol diphosphate obtained in step (h) under catalysis of a sclareol synthase (EC 4.2.3. 141) thereby obtaining the sclareol.
- steps (h) or (I2) is repeated at least once;
- steps (h) or (I2) is performed in a single reactor;
- Another aspect of the invention relates to a process for the preparation of a tetraterpenoid, comprising the process for the preparation of a tetraterpene, particularly comprising the process for the preparation of phytoene according to the invention as described above.
- the process additionally comprises the step of:
- step (m) reacting phytoene obtained in step (e) under catalysis of one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lycopene-a-cyclase (EC 5.5.1.18), lycopene [3-cyclase (EC 5.5.1.19) thereby obtaining the tetraterpenoid.
- one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lycopene-a-cyclase (EC 5.5.1.18), lycopene [3-cyclase (EC 5.5.1.19) thereby obtaining the tetraterpenoid.
- the tetraterpenoid is selected from the group consisting of phytofluene, 8-carotene, lycopene, neurosporene and [3-carotene.
- Another aspect of the invention relates to a process for the preparation of ionone, comprising the process for the preparation of a tetraterpenoid, particularly comprising the process for the preparation of [3-carotene according to the invention as described above.
- the process additionally comprises the step of:
- step (n) reacting the tetraterpenoid, particularly p-carotene, obtained in step (m) under catalysis of a carotenoid dioxygenase (EC 1.13.11.71 thereby obtaining ionone).
- a carotenoid dioxygenase EC 1.13.11.71
- P-carotene constitutes a particularly preferred choice
- other tetraterpenoids such as of phytoene, phytofluene, 8-carotene, lycopene, neurosporene represent suitable starting material from which ionone can be derived.
- (B) a monoterpene diphosphate (preferably encompassing steps (ai), (a2), (as), and (b));
- (C) a sesquiterpene diphosphate (preferably encompassing steps (ai), (a2), (as), and (c));
- (G) carvone (preferably encompassing steps (ai), (as), (as), (b), (f), (gi) and (gs));
- (H) a cannabinoide (preferably encompassing steps (ai), (as), (as), (b), (hi), (hs) and (hs));
- (L) sclareol (preferably encompassing steps (ai), (as), (as), (d), (h) and (E);
- any of the processes (A) to ( N) and all their preferred embodiments as described above take place at a temperature of 2.0 °C to 99.5 °C, or 3.0°C to 95.0°C, or 4.0°C to 90.0°C, or 5.0°C to 85.0°C, or 15.0°C to 80.0°C, or 25.0°C to 75.0°C, or 28.0°C to 75.0°C, or 30.0°C to 60.0°C, or 33.0°C to 50.0°C, or 35.0°C to 45.0°C.
- any of the processes (A) to ( N) and all their preferred embodiments as described above preferably take place in a liquid reaction medium, wherein said liquid reaction medium is characterized by a pH in the range of 5.0 to 8.5, or 5.3 to 8.5, or 5.5 to 8.5, or 5.8 to 8.5, or 6.0 to 8.5, or 6.4 to 8.5, or 6.6 to 8.5, or 6.9 to 8.5, 7.5 to 8.5, or 8.0 to 8.5.
- the processes (A) through (N) according to the invention comprise a phosphate regeneration system enabling the phosphorylation of the first, second, third, and/or fourth phosphate acceptor thereby regenerating the corresponding phosphate acceptor.
- any phosphate regeneration system known in the art can be employed.
- suitable phosphate regeneration systems may be polyphosphate kinase ATP regeneration systems, creatine kinase ATP regeneration systems, acetate kinase ATP regeneration systems, pyruvate kinase ATP regeneration systems, glucose-6-phosphate kinase ATP regeneration systems, fructose- 1,6- bisphosphate kinase ATP regeneration systems, 3 -phosphoglycerate kinase ATP regeneration systems.
- the process according to the invention may comprise the additional step of
- step (o) phosphorylating the first phosphate acceptor obtained in step (ai), the second phosphate acceptor obtained in step (a2), the third phosphate acceptor optionally obtained in step (as.i) and/or the fourth phosphate acceptor optionally obtained in step (a3.2) with a phosphorylating agent, optionally under catalysis of a fifth kinase, thereby obtaining first phosphate donor, second phosphate donor, third phosphate donor, and/or fourth phosphate donor, respectively.
- a "phosphorylating agent” is preferably to be interpreted as a phosphoryl-containing compound, i.e. organic or inorganic monophosphate or polyphosphate, which is capable of donating a phosphate unit to the first, second, third or fourth phosphate acceptor during the course of a reaction.
- the phosphorylating agent is polyphosphate, phosphocreatine, acetyl phosphate, phosphopyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, or 3 -phosphoglycerate; more preferably acetyl phosphate
- the "fifth kinase” is preferably an enzyme capable of catalyzing the phosphorylation of the first phosphate acceptor obtained in step (ai), the second phosphate acceptor obtained in step (a2), the third phosphate acceptor optionally obtained in step (as.i), and/or fourth phosphate acceptor optionally obtained in step (a3.2).
- the fifth kinase is an acetate kinase belonging to EC 2.7.2.1 or EC 2.7.4.1.
- the fifth kinase is an acetate kinase from Geobacillus kaustophilus, Escherichia coli, Rhodococcus erythropolis, Acinetobacter baylyi, Butyrivibrio fibrisolvens, Geobacillus caldoxylosilyti- cus, Bacillus amyloliquefaciens, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus shackletonii or Sinorhizobium meliloti.
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%,
- the fifth kinase according to the invention preferably comprises such an amino acid sequence with a defined identity to the amino acid sequence of SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, or SEQ ID NO:34, SEQ ID NO:35 SEQ ID NO:36 or SEQ ID NO:37.
- the fifth kinase according to the invention may comprise said amino acid sequence as a subsequence of its overall amino acid sequence, or that the fifth kinase according to the invention may essentially consist of said amino acid sequence.
- the Fifth kinase according to the invention comprises said amino acid sequence as a subsequence of its overall amino acid sequence
- said overall amino acid sequence may be extended, i.e. may comprise additional amino acid residues, at the N-terminus and/or at the C-terminus of said subsequence.
- Such extension may be advantageous, for example, when the fifth kinase is to be immobilized on a solid support, e.g. for purification purposes.
- the phosphorylating agent is acetyl phosphate
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least
- compositions comprising (i) first hemiterpene diphosphate obtainable by the process according to the invention as described above in combination with (ii) a first kinase, (iii) a first phosphate donor, (iv) a second kinase, and (v) a second phosphate donor or any combination of the foregoing.
- the composition further comprises (vi) a phosphorylating agent, and/or (vii) a fifth kinase, preferably wherein the phosphorylating agent is acetyl phosphate and/or wherein the fifth kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at
- the composition according to the invention further comprises a (i) monoterpene obtainable by the process according to the invention as described above in combination with a (ii) monoterpene synthase.
- the monoterpene is preferably selected from the group consisting of squalene 1,8-cineol, (-)-sabinene, (+)-sabinene, 5-carene and (R)-limonene, preferably wherein the monoterpene is squalene, (-)-sabinene, (+)-sabinene or 5-3-carene.
- the composition further comprises a (i) sesquiterpene diphosphate obtainable by the process according to the invention as described above in combination with a (ii) sesquiterpene diphosphate synthase.
- the composition further comprises a (i) sesquiterpene obtainable by the process according to the invention as described above in combination with a (ii) sesquiterpene synthase.
- the sesquiterpene is preferably selected from the group consisting of valencene, a-bisabolol, [3-bisabolene, patchoulol, [3-elemene, 5-cadinene, a-trans-bergamotene, [3-cis-bergamotene, P-trans-bergamotene, zingiberene, longifolene, a-santalene, -santalene.
- the composition further comprises a (i) sesquiterpenoid obtainable by the process according to the invention as described above in combination with a (ii) monooxygenase (EC 1.14.x.x).
- a (i) sesquiterpenoid obtainable by the process according to the invention as described above in combination with a (ii) monooxygenase (EC 1.14.x.x).
- the sesquiterpenoid is preferably selected from the group consisting of noot- katone, hemandulcin, a-santalol, -santalol.
- the composition further comprises a (i) diterpene diphosphate obtainable by the process according to the invention as described above in combination with a (ii) diterpene diphosphate synthase.
- the composition further comprises (i) sclareol obtainable by the process according to the invention as described above in combination with a (ii) labdenediol diphosphate and a sclareol synthase (EC 4.2.3.141).
- the composition further comprises a (i) tetraterpene obtainable by the process according to the invention as described above in combination with a (ii) tetraterpene synthase.
- the tetraterpene is preferably phytoene.
- the composition further comprises a (i) tetraterpenoid obtainable by the process according to the invention as described above in combination with (ii) one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lyco- pene-a-cyclase (EC 5.5.1.18), lycopene [3-cyclase (EC 5.5.1.19) thereby obtaining the tetraterpene
- a tetraterpenoid obtainable by the process according to the invention as described above in combination with (ii) one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lyco- pene-a-cyclase (EC 5.5.1.18), lycopene [3-cyclase (EC 5.5.1.19) thereby obtaining the t
- the tetraterpenoid is preferably selected from the group consisting of phyto- fluene, 8-carotene, lycopene, neurosporene and [3-carotene.
- the composition further comprises (i) ionone obtainable by the process according to the invention as described above in combination with a (ii) carotenoid dioxygenase (EC 1.13.11.71).
- Clause 1 A process for the preparation of a first hemiterpene diphosphate comprising the steps of: (ai) phosphorylating a first hemiterpene alcohol with a first phosphate donor under catalysis of a first kinase thereby obtaining a first hemiterpene monophosphate and a first phosphate acceptor; and (a2) phosphorylating the first hemiterpene monophosphate obtained in step (ai) with a second phosphate donor under catalysis of a second kinase thereby obtaining a first hemiterpene diphosphate and a second phosphate acceptor; wherein "terpene” encompasses terpenes as well as terpenoids according to IUPAC.
- Clause 2 The process according to clause 1, wherein the first kinase is an enzyme capable of catalyzing the phosphorylation of an alcohol; preferably of a hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isoprenol and/or prenol.
- the first kinase is an enzyme capable of catalyzing the phosphorylation of an alcohol; preferably of a hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isoprenol and/or prenol.
- Clause 3 The process of clauses 1 or 2, wherein the first kinase in an enzyme capable of catalyzing the transfer of a phosphate group; preferably wherein said first kinase is selected from the group consisting of:
- - phosphotransferase with alcohol group as acceptor preferably selected from the group consisting of ethanolamine kinase (EC 2.7.1.82), amide-alcohol kinase, ceramide kinase (EC 2.7.1.138), pantoate kinase (EC 2.7.1.169), undecaprenol kinase (EC 2.7.1.66), choline kinase (EC 2.7.1.32), glycerol kinase (EC 2.7.1.30), glycerone kinase (EC 2.7.1.29), mevalonate kinase (EC 2.7.1.30), and hydrox- yethylthiazole kinase (EC 2.7.1.50); and/or
- - phosphotransferases with a phosphate group as an acceptor EC 2.7.4; preferably selected from the group consisting of polyphosphate kinase, phosphomevalonate kinase, adenylate kinase, nucleoside- phosphate kinase, deoxycytidylate kinase, nucleoside-diphosphate kinase, phosphomethylpyrimidine kinase, guanylate kinase, dTMP kinase, nucleoside-triphosphate-adenylate kinase, (deoxy) adenylate kinase, T2-induced deoxynucleotide kinase, (deoxy)nucleoside-phosphate kinase, UMP/CMP kinase, thiamine-diphosphate kinase, thiamine-phosphate kinase, 3-phosphoglyce
- acetate kinase EC 2.7.2. 1
- acetate kinase acetate kinase (diphosphate), (EC2.7.2.12), phosphoglycerate kinase (GTP) (EC2.7.2.10)
- glutamate 5-ki- nase EC 2.7.2.11
- glutamate 1-kinase EC 2.7.2.13
- branched-chain-fatty-acid kinase EC 2.7.2.14
- propionate kinase EC 2.7.2.15
- 2-phosphoglycerate kinase EC 2.7.2.
- [amino group carrier protein] -L-2 -aminoadipate 6-kinase (EC 2.7.2.17), carbamate kinase (EC 2.7.2.2), phosphoglycerate kinase (EC 2.7.2.3), aspartate kinase (EC 2.7.2.4), formate kinase( EC 2.7.2.6), (EC2.7.2.6), butyrate kinase (EC 2.7.2.7), acetylglutamate kinase (EC 2.7.2.8).
- Clause 4 The process according to any of the preceding clauses, wherein the first kinase is a hydroxyethylthiazole kinase from Escherichia coli (EC 2.7.1.50).
- Clause 5 The process according to any of the preceding clauses, wherein the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least
- Clause 6 The process according to any of the preceding clauses, preferably according to any of clauses 1 to 3, wherein the first kinase is a choline kinase from Plasmodium falciparum (PfCK) (EC 2.7.1.32).
- PfCK Plasmodium falciparum
- Clause 7 The process according to any of the preceding clauses, preferably according to any of clauses 1 to 3 or 6 wherein the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 8 The process according to any of the preceding clauses, wherein step (ai) is performed in a liquid reaction medium and wherein the first kinase is employed in a concentration of at least 0.0001 mg/ml.
- step (ai) is performed in a liquid reaction medium and wherein the first kinase is employed in a concentration of at most 1000 mg/ml; preferably at most 100 mg/ml, more preferably at most 10 mg/ml.
- Clause 10 The process according to any of the preceding clauses, wherein the first hemiterpene alcohol is selected from the group consisting of isoprenol, 3-methyl-3-buten-2-ol, tiglic alcohol, angelicic alcohol, senecioic alcohol and isovaleric alcohol, 2-Methyl-2-propen-l-ol, 3 -methylene- 1 -pentanol, 2- hexen-l-ol, 4-penten-l-ol, 3 -thiopheneethanol, 4-methyl-4-penten-l-ol, 2-(Z)-hexen-l-ol, 2-butyn-l-ol, 3 -furanmethanol, 3-buten-l-ol, (2E)-buten-l-ol, 3-methyl-2-penten-l-ol, 3-butyn-l-ol, 3,4-dimethyl- (2E)-penten-l-ol, (2E)-butene-2 -methyl
- Clause 11 The process according to any of the preceding clauses, wherein the first hemiterpene alcohol is isoprenol or prenol,
- Clause 12 The process according to any of the preceding clauses, wherein the first hemiterpene alcohol is isoprenol.
- Clause 13 The process according to any of the preceding clauses, wherein the first hemiterpene alcohol is employed in a concentration of at least 0.1 mM; preferably of at least 0.5 mM, more preferably of at least 1.0 mM.
- Clause 14 The process according to any of the preceding clauses, wherein step (ai) is performed in a liquid reaction medium and wherein the first hemiterpene alcohol is employed in a concentration of at most 2000 mM; preferably at most 1500 mM, more preferably at most 1000 mM.
- the first phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the first phosphate donor is a nucleoside mono- or polyphosphate preferably selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, or 3-phospho- gly cerate.
- Clause 16 The process according to any of the preceding clauses, wherein the first phosphate donor is a triphosphorylated conjugate of a ribose or a deoxyribose with a nucleobase selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil.
- Clause 17 The process according to any of the preceding clauses, wherein the first phosphate donor is adenosine triphosphate.
- Clause 18 The process according to any of the preceding clauses, wherein step (ai) is performed in a liquid reaction medium and wherein the first phosphate donor is employed in a concentration of at least 0.001 mM; preferably at least 0.005 mM, more preferably at least 0.01 mM.
- step (ai) is performed in a liquid reaction medium and wherein the first phosphate donor is employed in a concentration of at most 1000 mM; preferably at most 100 mM, more preferably at most 10 mM.
- Clause 20 The process according to any of the preceding clauses, wherein the second kinase is an enzyme capable of catalyzing the phosphorylation of a phosphorylated alcohol; preferably of a phosphorylated hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isopentenyl monophosphate and/or dimethylallyl monophosphate.
- the second kinase is an enzyme capable of catalyzing the phosphorylation of a phosphorylated alcohol; preferably of a phosphorylated hemiterpene alcohol, and more preferably of catalyzing the phosphorylation of isopentenyl monophosphate and/or dimethylallyl monophosphate.
- Clause 21 The process according to any of the preceding clauses, wherein the second kinase in an enzyme capable of catalyzing the transfer of a phosphate group; preferably wherein said second kinase is a phosphotransferase with a phosphate group as acceptor; preferably selected from the group consisting of polyphosphate kinase (EC 2.7.4.
- phosphomevalonate kinase (EC 2.7.4.2), adenylate kinase (EC 2.7.4.3), nucleoside-phosphate kinase (EC 2.7.4.4), thiamine-diphosphate kinase (EC 2.7.4.15), thi- amone-phosphate kinase (EC 2.7.4.16), famesyl-diphosphate kinase (EC 2.7.4.18), isopentenyl phosphate kinase (EC 2.7.4.26), and famesyl phosphate kinase (EC 2.7.4.32), phosphotransferases with a carboxy group as acceptor (EC 2.7.2): acetate kinase (EC 2.7.2.1), acetate kinase (diphosphate), (EC2.7.2.12), phosphoglycerate kinase (GTP) (EC2.7.2.10), glutamate 5-kinase (EC 2.7.2.
- [amino group carrier protein] -L-2 -aminoadipate 6- kinase (EC 2.7.2.17), carbamate kinase (EC 2.7.2.2), phosphoglycerate kinase (EC 2.7.2.3), aspartate kinase (EC 2.7.2.4), formate kinase( EC 2.7.2.6), (EC2.7.2.6), butyrate kinase (EC 2.7.2.7), acetylglutamate kinase (EC 2.7.2.8).
- Clause 22 The process according to any of the preceding clauses, wherein the second kinase is a isopentenyl phosphate kinase (EC 2.7.4.26).
- Clause 23 The process according to any of the preceding clauses, wherein the second kinase is a isopentenyl phosphate kinase from Arabidopsis thaliana, Branchiostoma floridae, Methanolobus tindarius, Methanococcus vannielii, aus Roseiflexus castenholzii, Thermoplasma acidophilum, Methanothermo- bacterthermoautotropicus, Methanocaldococcus jannaschii, Haloferax volcanii, Sulfolobus solfataricus, Trichoplax adhaerens, or Methanosalsum zhilinae.
- the second kinase is a isopentenyl phosphate kinase from Arabidopsis thaliana, Branchiostoma floridae, Methanolobus tindarius, Methanococcus vannielii, aus Roseiflexus castenholzii,
- Clause 24 The process according to any of the preceding clauses, wherein the second kinase is a isopentenyl phosphate kinase from Roseiflexus castenholzii.
- Clause 25 The process according to any of the preceding clauses, wherein the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least
- Clause 26 The process according to any of the preceding clauses, preferably according to any of clauses 1 to 21 or 23, wherein the second kinase is a isopentenyl phosphate kinase from Methanolobus tindarius.
- Clause 27 The process according to any of the preceding clauses, preferably according to any of clauses 1 to 21 or 23 or 26, wherein the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%,
- Clause 28 The process according to any of the preceding clauses, wherein the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least
- Clause 29 The process according to any of the preceding clauses, wherein step (a2) is performed in a liquid reaction medium and wherein the second kinase is employed in a concentration of at least 0.0001 mg/ml.
- Clause 30 The process according to any of the preceding clauses, wherein step (a2) is performed in a liquid reaction medium and wherein the second kinase is employed in a concentration of at most 1000 mg/ml; preferably at most 100 mg/ml, most preferably at most 10 mg/ml.
- Clause 31 The process according to any of the preceding clauses, wherein the second phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the first phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, or 3-phospho- glycerate.
- the first phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, or 3-phospho- glycerate.
- Clause 32 The process according to any of the preceding clauses, wherein the second phosphate donor is a triphosphorylated conjugate of a ribose or a deoxyribose with a nucleobase selected from the group consisting of adenine, guanine, inosine, cytosine, thymine, and uracil.
- Clause 33 The process according to any of the preceding clauses, wherein the second phosphate donor is adenosine triphosphate.
- Clause 34 The process according to any of the preceding clauses, wherein step (ai) is performed in a liquid reaction medium and wherein the second phosphate donor is employed in a concentration of at least 0.001 mM; preferably at least 0.005 mM, most preferably at least 0.1 mM.
- Clause 35 The process according to any of the preceding clauses, wherein the second phosphate donor and the first phosphate donor have different molecular weights.
- Clause 36 The process according to any of the preceding clauses, wherein the second phosphate donor and the first phosphate donor differ by at least one methine group.
- Clause 37 The process according to any of the preceding clauses, wherein the second phosphate donor and the first phosphate donor differ by at most one methine group.
- Clause 38 The process according to any of the preceding clauses, wherein step (ai) is performed in a liquid reaction medium and wherein the second phosphate donor is employed in a concentration of at most 1000 mM; preferably at most 100 mM, most preferably at most 10 mM.
- Clause 39 The process according to any of the preceding clauses, wherein the second phosphate donor is the same as the first phosphate donor.
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- the first hemiterpene alcohol is isoprenol
- the first and second phosphate donor is adenosine triphosphate
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or
- Clause 41 A process for the preparation of a monoterpene diphosphate comprising the process according to any of the preceding clauses.
- Clause 42 The process according to any of the preceding clauses, preferably according to clause 41 additionally comprising the steps of:
- step (b) linking the first hemiterpene diphosphate obtained in step (as) with the second hemiterpene diphosphate provided in step (as) under catalysis of a monoterpene diphosphate synthase thereby obtaining the monoterpene diphosphate.
- Clause 43 The process according to any of the preceding clauses, preferably according to clause 42, wherein the second hemiterpene diphosphate is obtained in step (as) and/or in step (ai).
- Clause 44 The process according to any of the preceding clauses, preferably according to any of clauses 42 to 43, wherein the monoterpene diphosphate synthase is an enzyme capable of catalyzing the condensation of one unit of the first hemiterpene diphosphate obtained in step (as) with one unit of the second hemiterpene diphosphate provided in step (as).
- Clause 45 The process according to any of the preceding clauses, preferably according to any of clauses 42 to 44, wherein the monoterpene diphosphate synthase is a geranyl diphosphate synthase (GPPS) (EC 2.5.1.1).
- GPPS geranyl diphosphate synthase
- Clause 46 The process according to any of the preceding clauses, preferably according to any of clauses 41 to 44, wherein the monoterpene diphosphate is a geranyl diphosphate (GPP).
- GPP geranyl diphosphate
- Clause 47 The process according to any of the preceding clauses, preferably according to any of clauses 41 to 45 wherein
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the monoterpene diphosphate is geranyl pyrophosphate (GPP); and/or
- Clause 48 A process for the preparation of a sesquiterpene diphosphate comprising the process according to any of the preceding clauses, preferably according to any of clauses 1 to 40.
- Clause 49 The process according to any of the preceding clauses, preferably according to clause 48 additionally comprising the steps of:
- step (c) linking the first hemiterpene diphosphate obtained in step (as) with the second hemiterpene diphosphate provided in step (as) under catalysis of a sesquiterpene diphosphate synthase thereby obtaining the sesquiterpene diphosphate.
- Clause 50 The process according to any of the preceding clauses, preferably according to clause 49, wherein the second hemiterpene diphosphate is obtained in step (as) and/or in step (ai).
- Clause 51 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 50, wherein the sesquiterpene diphosphate synthase is an enzyme capable of catalyzing the sequential condensation of one or more units of the first hemiterpene diphosphate obtained in step (as) with one unit of the second hemiterpene diphosphate provided in step (as).
- the sesquiterpene diphosphate synthase is an enzyme capable of catalyzing the sequential condensation of one or more units of the first hemiterpene diphosphate obtained in step (as) with one unit of the second hemiterpene diphosphate provided in step (as).
- Clause 52 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 51, wherein the sesquiterpene diphosphate synthase is a famesyl diphosphate synthase (FPPS) (EC 2.5.1.10).
- FPPS famesyl diphosphate synthase
- Clause 53 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 52, wherein the sesquiterpene diphosphate synthase is an FPPS from Geobacillus stea- rothermophilus, Bos Taurus, Gallus gallus, Pseudomonas aeruginosa, Rhizosolenia setigera, Ricinus communis, Lupinus albus, Homo sapiens, Artemisia spiciformi or Abies grandis.
- the sesquiterpene diphosphate synthase is an FPPS from Geobacillus stea- rothermophilus, Bos Taurus, Gallus gallus, Pseudomonas aeruginosa, Rhizosolenia setigera, Ricinus communis, Lupinus albus, Homo sapiens, Artemisia spiciformi or Abies grandis.
- Clause 54 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 9
- Clause 55 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least
- Clause 56 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least
- Clause 57 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least
- Clause 58 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least
- Clause 59 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at
- Clause 60 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least
- Clause 61 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at
- Clause 62 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at
- Clause 63 The process according to any of the preceding clauses, preferably according to any of clauses 49 to 53, wherein the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at
- Clause 64 The process according to any clauses 48 to 63, wherein the sesquiterpene diphosphate is famesyl diphosphate (FPP).
- FPP famesyl diphosphate
- Clause 65 The process according to any of the preceding clauses, preferably according to any of clauses 48 to 64 wherein
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the sesquiterpene diphosphate is famesyl pyrophosphate (FPP); and/or
- the sesquiterpene diphosphate synthase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%
- Clause 66 A process for the preparation of a diterpene diphosphate comprising the process according to any of the preceding clauses, preferably according to any of clauses 1 to 40.
- Clause 67 The process according to any of the preceding clauses, preferably according to clause 66 additionally comprising the steps of:
- step (a2) providing a second hemiterpene diphosphate differing from the first hemiterpene diphosphate; and (d) linking the first hemiterpene diphosphate obtained in step (a2) with the second hemiterpene diphosphate provided in step (as) under catalysis of a diterpene diphosphate synthase thereby obtaining the diterpene diphosphate.
- Clause 68 The process according to any of the preceding clauses, preferably according to clause 67, wherein the second hemiterpene diphosphate is obtained in step (as) and/or in step (ai).
- Clause 69 The process according to any of the preceding clauses, preferably according to any of clauses 67 to 68, wherein the diterpene diphosphate synthase is an enzyme capable of catalyzing the sequential condensation of one or more unit of the first hemiterpene diphosphate obtained in step (as) with one unit of the second hemiterpene diphosphate provided in step (as).
- the diterpene diphosphate synthase is an enzyme capable of catalyzing the sequential condensation of one or more unit of the first hemiterpene diphosphate obtained in step (as) with one unit of the second hemiterpene diphosphate provided in step (as).
- Clause 70 The process according to any of the preceding clauses, preferably according to any of clauses 67 to 69, wherein the diterpene diphosphate synthase is a geranylgeranyl diphosphate synthase (GPPS) (EC 2.5.1.29).
- GPPS geranylgeranyl diphosphate synthase
- Clause 71 The process according to any of the preceding clauses, preferably according to any of clauses 66 to 70, wherein the diterpene diphosphate is geranylgeranyl diphosphate (GGPP).
- GGPP geranylgeranyl diphosphate
- Clause 72 The process according to any of the preceding clauses, preferably according to any of clauses 66 to 71, wherein
- the first hemiterpene diphosphate is isopentenyl pyrophosphate (IPP); and/or
- the diterpene diphosphate is geranylgeranyl pyrophosphate (GGPP); and/or
- the diterpene diphosphate synthase is a geranylgeranyl diphosphate synthase (GPPS) belonging to EC 2.5.1.29.
- GPPS geranylgeranyl diphosphate synthase
- Clause 73 A process for the preparation of a tetraterpene comprising the process for the preparation of a diterpene diphosphate according to any of the preceding clauses, preferably according to any of clauses 66 to 72.
- Clause 74 The process according to any of the preceding clauses, preferably according to clause 73 additionally comprising the step of:
- step (e) linking at least two units of the diterpene diphosphate obtained in step (d) under catalysis of a tetraterpene synthase thereby obtaining the tetraterpene.
- Clause 75 The process according to any of the preceding clauses, preferably according to clause 74, wherein the tetraterpene synthase is an enzyme capable of catalyzing the sequential condensation of two or more units of the diterpene diphosphate obtained in step (d).
- Clause 76 The process according to any of the preceding clauses, preferably according to any of clauses 74 to 75, wherein the tetraterpene synthase is a phytoene synthase (EC 2.5.1.32).
- Clause 77 The process according to any of the preceding clauses, preferably according to any of clauses 73 to 76, wherein the tetraterpene is phytoene.
- Clause 78 The process according to any of the preceding clauses, preferably according to any of clauses 73 to 77, wherein - the tetraterpene is phytoene; and/or
- the tetraterpene synthase is a phytoene synthase belonging to EC 2.5.1.32.
- step (as) comprises the substeps of
- step (as.2) phosphorylating the second hemiterpene monophosphate obtained in step (as.i) with a fourth phosphate donor under catalysis of a fourth kinase thereby obtaining the second hemiterpene diphosphate and a fourth phosphate acceptor.
- Clause 80 The process according to any of the preceding clauses, preferably according to clause 79, wherein the second hemiterpene alcohol is selected from the group consisting of isoprenol, 3-methyl-3- buten-2-ol, tiglic alcohol, angelicic alcohol, senecioic alcohol and isovaleric alcohol, 2-Methyl-2 -propen- l-ol, 3 -methylene- 1 -pentanol, 2-hexen-l-ol, 4-penten-l-ol, 3 -thiopheneethanol, 4-methyl-4-pen- ten-l-ol, 2-(Z)-hexen-l-ol, 2-butyn-l-ol, 3 -furanmethanol, 3-buten-l-ol, (2E)-buten-l-ol, 3 -methyl -2- penten-l-ol, 3-butyn-l-ol, 3,4-dimethyl-(2E)-penten-l
- Clause 81 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 80, wherein the second hemiterpene alcohol is preferably a constitutional isomer of the first hemiterpene alcohol.
- Clause 82 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 81, wherein the second hemiterpene alcohol is isoprenol or prenol,
- Clause 83 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 82, wherein the second hemiterpene alcohol is prenol.
- Clause 84 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 83, wherein the second hemiterpene alcohol is employed in a concentration of at least 0.1 mM; preferably of at least 0.5 mM, most preferably of at least 1.0 mM.
- Clause 85 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 84, wherein the second hemiterpene alcohol is employed in a concentration of at most 2000 mM; preferably at most 1500 mM, most preferably at most 1000 mM.
- Clause 86 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 85, wherein the third kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or
- Clause 87 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 86, wherein the fourth kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%,
- Clause 88 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 87, wherein the third phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the third phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6- phosphate, fructose- 1,6-bisphosphate, and 3 -phosphoglycerate.
- the third phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the third phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6- phosphate, fructose- 1,6-bisphosphate, and 3 -phosphoglycer
- Clause 89 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 88, wherein the third phosphate donor has the same molecular structure as the first and /or second phosphate donor.
- Clause 90 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 89, wherein the fourth phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the first phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6- phosphate, fructose- 1,6-bisphosphate, 3 -phosphoglycerate.
- the fourth phosphate donor is selected from the group consisting of organic and/or inorganic mono- or polyphosphates; preferably wherein the first phosphate donor is a nucleoside mono- or polyphosphate, phosphoenolpyruvic acid, acetyl phosphate, phosphoenolpyruvate, glucose-6- phosphate, fructose- 1,6-bisphosphate, 3 -phosphoglycerate.
- Clause 91 The process according to any of the preceding clauses, preferably according to any of clauses 78 to 90, wherein the fourth phosphate donor has the same molecular structure as the first and second and/or third phosphate donor.
- Clause 92 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 91, wherein the molar ratio of the first hemiterpene alcohol relative to second hemiterpene alcohol is at least 1 : 10, or at least 1 : 2, or preferably at least 1 : 1 , or most preferably at least 2 : 1 or 3 : 1.
- Clause 93 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 92, wherein the molar ratio of the first hemiterpene alcohol relative second hemiterpene alcohol is at most 100: 1; preferably at most 10 : 1 or at most 5 : 1 , or preferably at most 3: 1.
- Clause 94 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 93, wherein
- steps (ai), (a2), (as.i), (a-, 2) is repeated at least once;
- steps (ai), (a2), (as.i), (a-, 2) are performed in a single reactor; and/or
- step (as) comprises the substep of
- Clause 96 The process according to any of the preceding clauses, preferably according to clause 95, wherein the isomerase is selected from the group consisting of steroid delta isomerase (EC 5.3.3. 1), vinylacetyl-CoA delta isomerase (EC 5.3.3.3), muconolactone delta-isomerase (EC 5.3.3.4), 5-carbox- ymethyl-2-ydroxymuconate delta isomerase (EC 5.3.3.10), isopiperitenone delta-isomerase (EC 5.3.3.11), polyenoic fatty acid isomerase (EC 5.3.3.13), trans-2,3-dihydro-3-hydroxyanthranilate isomerase (EC 5.3.3.17), lutein isomerase (5.3.3.22) and isopentenyl diphosphate isomerase (EC 5.3.3.2).
- Clause 97 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 96, wherein the isomerase is a isopentenyl diphosphate
- Clause 98 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 97, wherein the isomerase is a isopentenyl diphosphate isomerase from Schizosaccharo- myces pombe, Claviceps purpurea, Phaffia rhodozyma, Homo sapiens, Sus scrofa, Gallus gallus, Sola- num lycopersicum, Haematococcus lacustris, Gossypium barbadense, Escherichia coli, or Saccharomy- ces cerevisiae.
- the isomerase is a isopentenyl diphosphate isomerase from Schizosaccharo- myces pombe, Claviceps purpurea, Phaffia rhodozyma, Homo sapiens, Sus scrofa, Gallus gallus, Sola- num lycopersicum, Haematococcus
- Clause 99 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least
- Clause 100 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%
- Clause 101 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%
- Clause 102 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 103 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least
- Clause 104 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 105 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 106 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 107 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 108 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 109 The process according to any of the preceding clauses, preferably according to any of clauses 95 to 98, wherein the isomerase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 9
- Clause 110 The process according to any of the preceding clauses, wherein the second hemiterpene diphosphate is selected from the group consisting of isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), 3-methyl-3-buten-2-ol diphosphate, tiglic alcohol diphosphate, angelicic alcohol diphosphate, senecioic alcohol diphosphate and isovaleric alcohol diphosphate.
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- 3-methyl-3-buten-2-ol diphosphate 3-methyl-3-buten-2-ol diphosphate
- tiglic alcohol diphosphate tiglic alcohol diphosphate
- angelicic alcohol diphosphate senecioic alcohol diphosphate
- isovaleric alcohol diphosphate isovaleric alcohol diphosphate.
- Clause 111 The process according to any of the preceding clauses, wherein the second hemiterpene diphosphate is a structural isomer; preferably a constitutional isomer of the first hemiterpene diphosphate.
- Clause 112 The process according to any of the preceding clauses, wherein the second hemiterpene diphosphate is isopentenyl pyrophosphate (IPP) or dimethylallyl pyrophosphate (DMAPP).
- IPP isopentenyl pyrophosphate
- DMAPP dimethylallyl pyrophosphate
- Clause 114 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 113, wherein
- steps (ai), (a2), (as.i), (as.2), (as s) is repeated at least once;
- steps (ai), (a2), (as.i), (as.2), (as s) are performed in a single reactor;
- steps (a-, 2) and (as s) are performed simultaneously;
- steps (a2) and (as s), are performed simultaneously.
- Clause 115 The process according to any of the preceding clauses, preferably according to any of clauses 79 to 114, wherein
- the first kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- the first hemiterpene alcohol is isoprenol
- the first, second, third and fourth phosphate donor is adenosine triphosphate
- the second kinase is an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%,
- step (as) comprises the sub-steps of:
- the isomerase is a isopentenyl diphosphate isomerases an enzyme comprising a primary sequence having an identity of at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in
- the second hemiterpene diphosphate is dimethylallyl pyrophosphate (DMAPP); and/or
- the third phosphate donor and fourth phosphate donor are adenosine triphosphate.
- Clause 116 A process for the synthesis of a monoterpene comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a monoterpene diphosphate according to any clauses 41 to 47 or any of clauses 79 to 115.
- Clause 117 The process according to any of the preceding clauses, preferably according to clause 116 additionally comprising the step of:
- step (f) reacting a monoterpene diphosphate obtained in step (b) under catalysis of a monoterpene synthase thereby obtaining the monoterpene.
- Clause 118 The process according to any of the preceding clauses, preferably according to clause 117, wherein the monoterpene synthase is an enzyme capable of catalyzing the rearrangement and/or cyclization of GPP into a monoterpene i.e.
- the monoterpene synthase is a an selected from the group consisting of squalenesynthase (EC 2.5.1.21), 1,8-cineol synthase, (EC 4.2.3.108), (-)-sabinene synthase (EC 4.2.3.109), (+)-sabinene synthase (EC 4.2.3.110), 5-carene-synthase (EC 4.2.3.107) and (R)-limonene synthase (EC 4.2.3.20), preferably wherein the monoterpene synthase is (-)-sabinene synthase (EC 4.2.3.
- Clause 120 A process for the synthesis of a carvone comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a monoterpene according to any clauses 116 to 119.
- Clause 121 The process according to any of the preceding clauses, preferably according to clause 119 additionally comprising the steps of:
- step (gi) reacting (R)-limonene obtained in step (f) under catalysis of a Limonene-6-hydroxylase (EC 1.14.13.48) thereby obtaining carvenol;
- Clause 122 The process according to any of the preceding clauses, preferably according to clause 121, wherein
- steps (gi) or (g 2 ) is repeated at least once;
- steps (gi) or (g 2 ) is performed in a single reactor;
- Clause 123 A process for the synthesis of a cannanbinoide comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a monoterpene diphosphate according to any clauses 41 to 47 or any of clauses 78 to 114.
- Clause 124 The process according to any of the preceding clauses, preferably according to clause 123 additionally comprising the steps of:
- step (hi) reacting a monoterpene, particularly GPP diphosphate obtained in step (b) with an olivetolic acid under catalysis of an aromatic prenyltransferase thereby obtaining cannabigerolic acid;
- CBDA cannabidiol
- THC tetrahydrocannabinol
- Clause 125 The process according to any of the preceding clauses, preferably according to clause 124 wherein the aromatic prenyltransferase is a an selected from the group consisting of aspulvinone dimethylallyltransferase (EC 2.5.1.35), trihydroxypterocarpan dimethylallyltransferase (EC 2.5.1.36), 4- hydroxybenzoic acid oligoprenyltransferase (EC 2.5.1.39), naringenin 8 -dimethylallyltransferase (EC 2.5.1.70), 4-hydroxybenzoate geranyltransferase (EC 2.5.1.93), fumigaclavine A dimethylallyltransferase (EC 2.5.1.100), geranylpyrophosphate: olivetolate geranyltransferase (EC 2.5.1.102), 4-hydroxy- phenylpyruvate: dimethylallyl transferase (EC 2.5.1.111), homogentisate geranylgeranyltransferas
- Clause 126 The process according to any of the preceding clauses, preferably according to clause 124, wherein
- steps (hi) (I12) or (h ) is repeated at least once;
- steps (hi) (I12) or (I13) is performed in a single reactor;
- Clause 127 A process for the synthesis of a sesquiterpene comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a sesquiterpene diphosphate according to any clauses 48 to 65 or any of clauses 79 to 115.
- Clause 128 The process according to any of the preceding clauses, preferably according to clause 127 additionally comprising the step of:
- step (i) reacting a sesquiterpene diphosphate obtained in step (c) under catalysis of a sesquiterpene synthase thereby obtaining the sesquiterpene.
- Clause 129 The process according to any of the preceding clauses, preferably according to clause 127 and/or 128, wherein the sesquiterpene synthase is an enzyme capable of catalyzing the rearrangement and/or cyclization of FPP into a sesquiterpene i.e.
- the sesquiterpene synthase is a an enzyme selected from the group consisting of valencene synthase (EC 4.2.3.73), a-bisabolol-synthase (EC 4.2.3.138), (S)-beta-bisabolene synthase (EC 4.2.3.55), patchoulol synthase (EC 4.2.3.70), p-elemene synthase (EC 4.2.3.x), 5-cadinene synthase (EC 4.2.3.13), (+)-endo-beta-bergamotene synthase (EC 4.2.3.53), (-)-endo-alpha-bergamo- tene synthase (EC 4.2.3.54), exo-alpha-bergamotene synthase (EC 4.2.3.81), zingiberene synthase (EC 4.2.3.65), longifolene synthase (4.2.
- Clause 130 The process according to any of the preceding clauses, preferably according to any of clauses 127 to 129, wherein the sesquiterpene is selected from the group consisting of valencene, a- bisabolol, P-bisabolene, patchoulol, P-elemene, 5-cadinene, a-trans-bergamotene, P-cis-bergamotene, P- trans-bergamotene, zingiberene, longifolene, a-santalene, P-santalene.
- the sesquiterpene is selected from the group consisting of valencene, a- bisabolol, P-bisabolene, patchoulol, P-elemene, 5-cadinene, a-trans-bergamotene, P-cis-bergamotene, P- trans-bergamotene, zingiberene, longifolene, a-santalene, P-santalene
- Clause 131 A process for the synthesis of a sesquiterpenoid comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a sesquiterpene according to any clauses 127 to 130.
- Clause 132 The process according to any of the preceding clauses, preferably according to clause 131 additionally comprising the steps of:
- Clause 134 A process for the synthesis of a famesol comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a sesquiterpene diphosphate according to any clauses 48 to 65 or any of clauses 79 to 115.
- Clause 135 The process according to any of the preceding clauses, preferably according to clause 134 additionally comprising the steps of:
- step (k) reacting a sesquiterpene diphosphate obtained in step (c) under catalysis of a FPP-diphosphatase thereby obtaining fame sol.
- Clause 136 The process according to any of the preceding clauses, preferably according to clause 135 wherein the FPP-diphosphatase is a phosphatase belonging to EC 3.6.1.x and/or EC 3.1.3.x.
- Clause 137 A process for the synthesis of a sclareol comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a diterpene diphosphate according to any clauses 66 to 72 or any of clauses 79 to 115.
- Clause 138 The process according to any of the preceding clauses, preferably according to clause 137 additionally comprising the step of:
- step (h) reacting a diterpene diphosphate, particularly GGPP, obtained in step (d) under catalysis of a labdenediol synthase (EC 4.2.1.133) thereby obtaining the labdenediol diphosphate (LDPP); and
- step (h) reacting labdenediol diphosphate obtained in step (h) under catalysis of a sclareol synthase (EC 4.2.3. 141) thereby obtaining the sclareol.
- Clause 139 The process according to any of the preceding clauses, preferably according to any of clauses 137 to 138, wherein
- steps (h) or (I2) is repeated at least once;
- steps (h) or (I2) is performed in a single reactor;
- Clause 140 A process for the synthesis of a tetraterpenoid comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a tetraterpene according to any clauses 73 to 78 or any of clauses 79 to 115.
- Clause 141 The process according to any of the preceding clauses, preferably according to clause 140 additionally comprising the step of:
- step (m) reacting phytoene obtained in step (e) under catalysis of one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lycopene-a-cyclase (EC 5.5.1.18), lycopene P-cyclase (EC 5.5.1.19) thereby obtaining the tetraterpene.
- Clause 142 The process according to any of the preceding clauses, preferably according to clause 141, wherein the tetraterpenoid is selected from the group consisting of phytofluene, 8-carotene, lycopene, neurosporene and P-carotene.
- Clause 143 A process for the synthesis of ionone comprising the process according to any of the preceding clauses, preferably comprising the process for the synthesis of a tetraterpenoid according to any clauses 140 to 142.
- Clause 144 The process according to any of the preceding clauses, preferably according to clause 143 wherein the process comprises the additional step of:
- step (n) reacting the tetraterpenoid obtained in step (m) under catalysis of a carotenoid dioxygenase (EC 1.13.11.71 thereby obtaining ionone) .
- Clause 145 The process according to any of the preceding clauses, preferably according to clause 144, wherein the tetraterpenoid is selected from the group consisting of phytoene, phytofluene, 8-carotene, lycopene, neurosporene and P-carotene.
- step (o) phosphorylating the first phosphate acceptor obtained in step (ai), the second phosphate acceptor obtained in step (a2), the third phosphate acceptor optionally obtained in step (as.i) and/or the fourth phosphate acceptor optionally obtained in step (a3.2) with a phosphorylating agent, optionally under catalysis of a fifth kinase, thereby obtaining first phosphate donor, second phosphate donor, third phosphate donor, and/or fourth phosphate donor, respectively.
- Clause 147 The process according to any of the preceding clauses, preferably according to clause 146, wherein the phosphorylating agent is acetyl phosphate, polyphosphate, phosphocreatine, acetyl phosphate, phosphopyruvate, glucose-6-phosphate, fructose- 1,6-bisphosphate, 3 -phosphoglycerate, preferably wherein the phosphorylating agent is acetyl phosphate
- Clause 148 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 147, wherein the fifth kinase is an enzyme capable of catalyzing the phosphorylation of the first phosphate acceptor obtained in step (ai), the second phosphate acceptor obtained in step (a2) and/or the third phosphate acceptor optionally obtained in step (as.i).
- the fifth kinase is an enzyme capable of catalyzing the phosphorylation of the first phosphate acceptor obtained in step (ai), the second phosphate acceptor obtained in step (a2) and/or the third phosphate acceptor optionally obtained in step (as.i).
- Clause 149 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 148, wherein the fifth kinase is an acetate kinase belonging to EC 2.7.2. 1 or EC 2.7.4.1.
- Clause 150 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 149, wherein the fifth kinase is an acetate kinase from Geobacillus kaustophilus, Escherichia coli, Rhodococcus erythropolis, Acinetobacter baylyi, Butyrivibrio fibrisolvens, Geobacillus cald- oxylosilyticus, Bacillus amyloliquefaciens, Bacillus licheniformis, Bacillus megaterium, Bacillus pu- milus, Bacillus shackletonii or Sinorhizobium meliloti.
- the fifth kinase is an acetate kinase from Geobacillus kaustophilus, Escherichia coli, Rhodococcus erythropolis, Acinetobacter baylyi, Butyrivibrio fibrisolvens, Geobacillus cald- oxylosilyticus, Bacillus am
- Clause 151 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 152 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 153 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 154 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 155 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 156 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 157 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 158 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least
- Clause 159 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 160 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least
- Clause 161 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 162 The process according to any of the preceding clauses, preferably according to any of clauses 146 to 150, wherein the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at
- Clause 163 The process according to any of the preceding clauses, preferably according to any of clauses to clauses 146 to 162, wherein
- the phosphorylating agent is acetyl phosphate
- the fifth kinase is an enzyme comprising a primary sequence having an identity at least 60%, or at least 61%, or at least 62%, or at least 63%, or at least 64%; preferably at least 65%, or at least 66%, or at least 67%, or at least 68%, or at least 69%; more preferably at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%; still more preferably at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%; yet more preferably at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%; even more preferably at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%; most preferably at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%; and in particular at least 95%, or at least 96%, or
- Clause 164 The process according to any of the preceding clauses, wherein the process take place at a temperature of 2.0 °C to 99.5 °C, or 3.0°C to 95.0°C, or 4.0°C to 90.0°C, or 5.0°C to 85.0°C, or 15.0°C to 80.0°C, or 25.0°Cto 75.0°C, or 28.0°Cto 75.0°C, or 30.0°C to 60.0°C, or 33.0°C to 50.0°C, or 35.0°C to 45.0°C.
- Clause 165 The process according to any of the preceding clauses, wherein the process take place in a liquid reaction medium, wherein said liquid reaction medium is characterized by a pH in the range of 5.0 to 8.5, or 5.3 to 8.5, or 5.5 to 8.5, or 5.8 to 8.5, or 6.0 to 8.5, or 6.4 to 8.5, or 6.6 to 8.5, or 6.9 to 8.5, 7.5 to 8.5, or 8.0 to 8.5.
- Clause 166 A composition comprising a (i) first hemiterpene diphosphate obtainable by the process according to any of the proceeding clauses in combination with (ii) a first kinase, (iii) a first phosphate donor, (iv) a second kinase, and (v) a second phosphate donor or any combination of the foregoing.
- Clause 167 The composition according to clause 166 further comprising a (i) monoterpene diphosphate obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 41 to 47 or any of clauses 79 to 115 in combination with a (ii) monoterpene diphosphate synthase.
- Clause 168 The composition according to any of clauses 166 or 167 further comprising a (i) monoterpene obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 116 to 119 or any of clauses 79 to 115 in combination with a (ii) monoterpene synthase.
- Clause 169 The process according to clause 167, wherein the monoterpene is selected from the group consisting of squalene 1,8-cineol, (-)-sabinene, (+)-sabinene, 5-carene and (R)-limonene, preferably wherein the monoterpene is squalene, (-)-sabinene, (+)-sabinene or 5-3-carene.
- Clause 170 The composition according to any of clauses 166 to 169 further comprising a (i) sesquiterpene diphosphate obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 48 to 65 or any of clauses 79 to 115 in combination with a (ii) sesquiterpene diphosphate synthase.
- Clause 171 The composition according to clause 170 further comprising a (i) sesquiterpene obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 127 to 130 or any of clauses 79 to 115 in combination with a (ii) sesquiterpene synthase.
- Clause 172 The composition according to clause 171, wherein the sesquiterpene is selected from the group consisting of valencene, a-bisabolol, P-bisabolene, patchoulol, P-elemene, 5-cadinene, a-trans- bergamotene, P-cis-bergamotene, P-trans-bergamotene, zingiberene, longifolene, a-santalene, P-san- talene.
- the sesquiterpene is selected from the group consisting of valencene, a-bisabolol, P-bisabolene, patchoulol, P-elemene, 5-cadinene, a-trans- bergamotene, P-cis-bergamotene, P-trans-bergamotene, zingiberene, longifolene, a-santalene, P-san- talene.
- Clause 173 The composition according to any of clauses 166 to 171 further comprising a (i) sesquit- erpenoid obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 131 to 133 or any of clauses 79 to 115 in combination with a (ii) monooxygenase (EC 1.14.x.x).
- Clause 174 The composition according to clause 173, wherein the sesquiterpenoid is selected from the group consisting of nootkatone, hemandulcin, a-santalol, P-santalol.
- Clause 175 The composition according to any of clauses 166 to 174 further comprising a (i) diterpene diphosphate obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 66 to 72 or any of clauses 79 to 115 in combination with a (ii) diterpene diphosphate synthase.
- Clause 176 The composition according to clause 175 further comprising a (i) sclareol obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 137 to 139 in combination with a (ii) labdenediol diphosphate and a sclareol synthase (EC 4.2.3.141).
- Clause 177 The composition according to any of clauses 166 to 176 further comprising a (i) tetraterpene obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 73 to 78 or any of clauses 79 to 115 in combination with a (ii) tetraterpene synthase.
- Clause 178 The composition according to any clause 177, wherein the tetraterpene is phytoene.
- Clause 179 The composition according to any of clauses 166 to 178 further comprising a (i) tetraterpenoid obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 140 to 142 or any of clauses 79 to 115 in combination with (ii) one or more enzyme selected from the group consisting of phytoene desaturase (EC 1.3.99.31), ⁇ -carotene desaturase (EC 1.3.99.26), lycopene-a-cyclase (EC 5.5.1.18), lycopene [3-cyclase (EC 5.5.1.19) thereby obtaining the tetraterpene Clause 180: The composition according to clause 179, wherein the tetraterpenoid is selected from the group consisting of phytofluene, 8-carotene, lycopene, neurosporene and [3-carotene.
- Clause 181 The composition according to any of clauses 166 to 180 further comprising a (i) ionone obtainable by the process according to any of the preceding clauses, preferably according to any of clauses 143 to 145 or any of clauses 79 to 115 in combination with a (ii) carotenoid dioxygenase (EC 1.13.11.71).
- Cloning The genes were cloned into the expression vector pLElA18 (derivative of pRSF-lb, Novagen) containing an N-terminal Hise-tag for purification of the enzymes. The resulting plasmids were each used for transformation of E. coli BL21(DE3) cells.
- the eluted solution was rebuffered into 100 mM Tris-HCl-buffer pH 7,5, 150 mM NaCl, 10% (v/v) glycerol using PD-10 desalting columns according to the manufacturer (GE Healthcare). Aliquots of the purified enzyme solution were shock frozen in liquid nitrogen and stored at -20 °C.
- EcHTK For the determination of the standard activity of EcHTK (SEQ ID NO: 1), the synthesis of IP (isoprenol) from IOH (isoprenol) and ATP was assayed.
- An EcHTK (SEQ ID NO: 1) unit (U) corresponds to the synthesis of 1 pmol IP per minute from 100 mM IOH and 1,25 mM ATP in 200 mM Tris-HCL buffer pH 8.5, 50 mM MgCl 2 , 150 mM PolyP, 0. 1 mg/ml SmPPK (SEQ ID NO:37) at 30 °C. Reaction progress was determined discontinuously by stopping reaction after a given reaction time through heating at 90 °C for 10 min and quantifying the amount of synthesized IP via HPLC calibrated with an external standard.
- RcIMK SEQ ID NO:3
- IPP IPP from IP and ATP
- An RcIMK (SEQ ID NO:3) unit (U) corresponds to the synthesis of 1 pmol IPP per minute from 50 mM IP and 5 mM ATP in 200 mM Tris-HCL buffer pH 8.5, 20 mM MgC’T. 100 mM AcP, 5 U/ml GkACK (SEQ ID NO:26) at 30 °C. Reaction progress was determined discontinuously by stopping reaction after a given reaction time through heating at 90 °C for 10 min and quantifying the amount of synthesized IP via HPLC calibrated with an external standard.
- GsFPPS SEQ ID NO:5
- a GsFPPS unit (U) corresponds to the synthesis of 1 pmol FPP per minute from 1 mM IPP and 1 mM DMAPP in 50 mM Tris-HCL buffer pH 7.5, 0.40 mM MgC’T at 30 °C. Reaction progress was determined discontinuously by stopping reaction after a given reaction time by adding one volume of abs. MeOH and quantifying the amount of synthesized IP via HPLC calibrated with an external standard.
- EXAMPLE 2 Screening of different kinase for the synthesis of the IP and DMAP
- EXAMPLE 3 Synthesis of IPP and DMAPP under employment of a polyphosphate-based ATP- regeneration system.
- EXAMPLE 3.2 Synthesis of DMAPP - under employment of an Isomerase
- IPP isopentenyl diphosphate
- DMAPP dimethylallyl diphosphate
- a reaction containing 50 mM IPP, 5 mM MgCT and 0.2 mg/ml SpIDI (SEQ ID NO: 15) in 50 mM Tris-HCl, pH 7.5 was used.
- the reaction was incubated at 30 °C for 5 h to give Dimethylallyl pyrophosphate DMAPP.
- the isomerization from IPP to DMAPP can either be performed in a separate step, as described here. Or it can be coupled to the reaction from IOH to IPP described in example 3.1.
- the DMAPP yield can be significantly increased as compared to the case in which a polyphosphate-based ATP-regeneration system with SmPPK (SEQ ID NO:37) and PolyP is used.
- SmPPK SEQ ID NO:37
- the chemical driving force of the reaction with AcP as phosphate donor is significantly higher, so that the reaction equilibrium of RcIMK (SEQ ID NOT) is shifted more strongly to the product side.
- EXAMPLE 4.4 Comparative synthesis of IPP under employment of an acetyl phosphate-based ATP-regeneration system or a polyphosphate-based ATP-regeneration system.
- reaction mixtures were incubated at 30°C for 20 h, stopped by heating at 90 °C for 10 min and the resulting IPP quantified via HPLC, calibrated with an external standard.
- the resulting yield was 80 % IPP with GkACK (SEQ ID NO:26) and 8 % IPP with SmPPK (SEQ ID NO:37).
- the reaction was started by adding GsFPPS (SEQ ID NO:5) to a final concentration of 0,2 mg/ml.
- the mixture was incubated at 30 °C for 4-6 h, stopped by adding one volume of abs. MeOH and the resulting FPP was quantified via HPLC, calibrated with an external standard.
- EXAMPLE 6 General synthesis of sesquiterpenes starting from IOH under employment of a polyphosphate-based ATP-regeneration system
- EXAMPLE 7 General synthesis of sesquiterpenes starting from POH under employment of a polyphosphate-based ATP-regeneration system
- EXAMPLE 8 General synthesis of sesquiterpenes starting from IOH and POH under employment of a polyphosphate-based ATP-regeneration system
- EXAMPLE 9 General synthesis of sesquiterpenes starting from IOH and acetyl phosphate under employment of a acetyl phosphate -based ATP-regeneration system
- EXAMPLE 11 General synthesis of sesquiterpenes starting from IOH and POH under employment of a acetyl phosphate -based ATP-regeneration system
Abstract
L'invention concerne un procédé de production d'isoprénoïdes par une plate-forme de synthèse in vitro impliquant au moins les étapes de phosphorylation d'un premier alcool hémiterpénique avec un premier donneur de phosphate sous la catalyse d'une première kinase, obtenant ainsi un premier hémiterpène monophosphate, et de phosphorylation de ce dernier avec un second donneur de phosphate sous la catalyse d'une seconde kinase, obtenant ainsi au moins un premier hémiterpène diphosphate. L'invention concerne en outre une composition comprenant un premier hémiterpène diphosphate pouvant être obtenu par le procédé selon l'invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21152478 | 2021-01-20 | ||
EP21152479 | 2021-01-20 | ||
PCT/EP2022/051100 WO2022157180A1 (fr) | 2021-01-20 | 2022-01-19 | Plate-forme de synthèse in-vitro pour la génération d'isoprénoïdes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4281570A1 true EP4281570A1 (fr) | 2023-11-29 |
Family
ID=79927280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22700507.1A Pending EP4281570A1 (fr) | 2021-01-20 | 2022-01-19 | Plate-forme de synthèse in-vitro pour la génération d'isoprénoïdes |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4281570A1 (fr) |
WO (1) | WO2022157180A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011009132A2 (fr) | 2009-07-17 | 2011-01-20 | The Salk Institute For Biological Studies | Procédés et composition pour la synthèse du diphosphate disoprénoïde |
EP2553108A4 (fr) * | 2010-03-31 | 2015-01-28 | Codexis Inc | Production de monoterpènes |
US10428347B2 (en) | 2017-07-24 | 2019-10-01 | Spogen Biotech Inc. | Herbicide-detoxifying enzymes and uses thereof |
WO2019232025A2 (fr) | 2018-05-29 | 2019-12-05 | Massachusetts Institute Of Technology | Production technologique de microbes pour produire des isoprénoïdes |
WO2020150340A1 (fr) | 2019-01-15 | 2020-07-23 | North Carolina State University | Isoprénoïdes et leurs procédés de fabrication |
CA3162957A1 (fr) * | 2019-12-26 | 2021-07-01 | James U. Bowie | Plate-forme de biosynthese pour la production de cannabinoides et d'autres composes prenyles |
-
2022
- 2022-01-19 EP EP22700507.1A patent/EP4281570A1/fr active Pending
- 2022-01-19 WO PCT/EP2022/051100 patent/WO2022157180A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022157180A1 (fr) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Szkopińska et al. | Farnesyl diphosphate synthase; regulation of product specificity. | |
Kellogg et al. | Chain elongation in the isoprenoid biosynthetic pathway | |
Wang et al. | Isoprenyl diphosphate synthases | |
Jones et al. | Structure and synthesis of polyisoprenoids used in N-glycosylation across the three domains of life | |
Berthelot et al. | Isopentenyl diphosphate isomerase: a checkpoint to isoprenoid biosynthesis | |
Wang et al. | Engineered isoprenoid pathway enhances astaxanthin production in Escherichia coli | |
Wang et al. | Chain-length determination mechanism of isoprenyl diphosphate synthases and implications for molecular evolution | |
Burke et al. | Interaction with the small subunit of geranyl diphosphate synthase modifies the chain length specificity of geranylgeranyl diphosphate synthase to produce geranyl diphosphate | |
Han et al. | Fermentative production and direct extraction of (−)-α-bisabolol in metabolically engineered Escherichia coli | |
Faraldos et al. | A 1, 6-ring closure mechanism for (+)-δ-cadinene synthase? | |
Kharel et al. | Molecular analysis of cis-prenyl chain elongating enzymes | |
Drummond et al. | Expanding the isoprenoid building block repertoire with an IPP methyltransferase from Streptomyces monomycini | |
JP6231011B2 (ja) | 3−ヒドロキシアルク−4−エノエートおよび/または3−ホスホノキシアルク−4−エノエートの酵素変換による1,3−ジエンの産生 | |
EP2245161B1 (fr) | Procédé de production de sclaréol | |
Liang | Reaction kinetics, catalytic mechanisms, conformational changes, and inhibitor design for prenyltransferases | |
Ogura et al. | Polyprenyl diphosphate synthases | |
US20190367950A1 (en) | Microbial engineering for the production of isoprenoids | |
Ogawa et al. | A cis‐prenyltransferase from Methanosarcina acetivorans catalyzes both head‐to‐tail and nonhead‐to‐tail prenyl condensation | |
US20220162188A1 (en) | Isoprenoids and methods of making thereof | |
Kainou et al. | Identification of the GGPS1 genes encoding geranylgeranyl diphosphate synthases from mouse and human | |
Couillaud et al. | Simplified in vitro and in vivo bioaccess to prenylated compounds | |
Kang et al. | Secondary metabolism for isoprenoid-based biofuels | |
Couillaud et al. | Extension of the terpene chemical space: the very first biosynthetic steps | |
Rinkel et al. | Characterisation of three terpene synthases for β-barbatene, β-araneosene and nephthenol from social amoebae | |
EP4281570A1 (fr) | Plate-forme de synthèse in-vitro pour la génération d'isoprénoïdes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230705 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |